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CAUSES AND CONSEQUENCES OF GENETIC ROBUSTNESS
AND FRAGILITY IN HIV-1 PROTEINS

Suzannah J. Rihn, Ph.D.
The Rockefeller University 2014
Genetic robustness describes a capacity to maintain function in the face of
mutation. RNA viruses, like human immunodeficiency virus-1 (HIV-1),
experience extremely high mutations rates in vivo, which contribute to the
evolvability that permits HIV-1 to evade immune defenses. However, the
compact nature of the HIV-1 viral genome, in which small or overlapping proteins
are often multifunctional and essential, often necessitates a strong pressure to
conserve functional roles, which is at opposition with immunological pressures to
diversify. Under such conditions, and in consideration of the relatively rapid
replication cycle of HIV-1, natural selection for robustness would be predicted to
be beneficial. At the same time, robustness can come at the cost of fitness, and
it is unclear whether robustness or fitness would constitute the dominant
selective force in the natural setting.
Within a given virus, genetic robustness is expected to vary amongst
proteins, in accordance with specific function. Therefore, to more accurately
examine genetic robustness within HIV-1, we selected one protein in which the
competing needs to both conserve function yet diversify sequence is particularly
acute. HIV-1 capsid (CA) is under strong pressure to preserve roles in viral

assembly, maturation, uncoating and nuclear import, but is also under intense
immunological pressure to diversify, particularly from adaptive immune
responses. To evaluate the genetic robustness of HIV-1 CA, we generated a
large library of random single amino acid substitution CA mutants. Surprisingly,
after measuring the replicative fitness of the CA library mutants, we observed
HIV-1 CA to be the most genetically fragile protein analyzed with such an
approach, with 70% of random CA mutations resulting in nonviable, replicationdefective viruses (<2% of WT fitness). While CA is involved in several steps of
HIV-1 replication, analyses of conditionally (temperature-sensitive) and
constitutively nonviable mutants indicated that the biological basis for the genetic
fragility, or lack of robustness, was principally the need to organize accurate and
efficient assembly of mature viral particles.
Examination of the CA library mutations in naturally occurring HIV-1
subtype B populations indicated that all mutations occurring at a frequency >3%
in vivo had fitness levels that were >40% of WT in vitro. Moreover, protective
CTL epitopes were observed to preferentially occur in regions of HIV-1 CA that
were even more genetically fragile than HIV-1 CA as a whole. Overall, these
results suggest the extreme genetic fragility of CA may explain why immune
responses to Gag, as opposed to other viral proteins, correlate with better
prognosis in HIV-1 infection.
To evaluate whether the fragility we observed in CA was unique to CA or a
general property of HIV-1 proteins, and to more firmly establish causes and

consequences of genetic robustness or fragility, we evaluated the robustness of
another HIV-1 protein, integrase (IN). Again, a large library of unbiased single
amino acid mutants was created. In contrast to CA, IN appeared comparatively
robust, with only 35% of 156 single amino acid mutations resulting in nonviable
viruses. However, when these nonviable mutants were mapped onto a model of
the HIV-1 intasome, we noted a striking localization of nonviable mutants to
certain IN subunit interfaces. To this end, single mutants affecting both particle
production and IN expression in virions could be mapped to even more specific
regions within the intasome model. Furthermore, after examining the prevalence
of the IN library mutations in an in vivo cohort of subtype B IN sequences,
mapping to the intasome helped explain why some in vitro library mutations with
high fitness (>40% of WT) never occur in vivo, and also revealed that residues
that are highly variable in vivo are more likely to occur in regions in the intasome
with more exposed surface area. Despite the relative robustness of HIV-IN, our
analyses with an intasome model demonstrate that localized regions of fragility,
namely certain subunit interfaces, exist.
Understanding the genetic robustness of HIV-1 is particularly important
given the continued need for novel therapeutic interventions. Not only has the
evaluation of HIV-1 CA and IN robustness revealed particularly fragile regions in
both proteins, which may prove ideal targets, but comparisons of their genetic
robustness is suggestive of the direction future therapeutic research should take.

ACKNOWLEDGEMENTS
I would like to first acknowledge the guidance and mentorship I have received
from Dr. Paul Bieniasz. Not only has he been integral to the development of my
thesis work, but his flexibility and support throughout my time in his lab has
meant a great deal.
Importantly, Dr. Sam Wilson must also be acknowledged for his important
contributions to this work. As the creator of the mutagenized capsid library, a
significant portion of my work relied on what he had previously generated.
However, he has also been an extremely valuable source of advice and
encouragement.
Furthermore, I would like to thank my collaborators. Both Dr. Rob Gifford and Dr.
Joseph Hughes provided tremendous help with bioinformatics analyses. Dr.
Frazer Rixon and Dr. Saskia Bakker also provided important electron microscopic
analyses. Additionally, our examinations of the HIV-1 intasome model structure
would not have been possible without the structure coordinates provided by Dr.
Stephen Hughes and his laboratory. I would also like to thank Dr. Mike Malim for
generously providing a valuable reagent, the INT4 antibody.
Finally, I would like to thank the members of my thesis committee, Dr. Charles
Rice, Dr. Nina Papavasiliou, and Dr. Rob Gifford for their valued discussions and
direction.

iii

TABLE OF CONTENTS
Acknowledgements ............................................................................................ iii
Table of Contents ................................................................................................. iv
List of Figures ....................................................................................................... vii
List of Tables ........................................................................................................ ix
I. INTRODUCTION ................................................................................................ 1
Retroviridae and human immunodeficiency virus-1 (HIV-1) .................. 1
Genetic robustness and fragility .......................................................... 11
HIV-1 capsid (CA) ............................................................................... 20
HIV-1 integrase (IN) ............................................................................ 27
II. MATERIALS AND METHODS ........................................................................ 35
Plasmids .............................................................................................. 35
Construction of CA and IN mutant libraries ......................................... 37
Cell lines and transfection ................................................................... 39
Primary cells ........................................................................................ 40
Viral replication and infectivity assays ................................................. 41
Western blotting .................................................................................. 44
Structure analysis ................................................................................ 45
Thin-section microscopy...................................................................... 45
Cryo-electron microscopy.................................................................... 46
Analysis of natural CA and IN variants ................................................ 47
III. RESULTS ....................................................................................................... 49
Chapter 1. HIV-1 CA and creation of a randomly mutagenized CA
library ........................................................................................................ 49
1. Introduction to surveying the robustness of CA through
random mutagenesis ................................................................ 49
2. Creation of the CA randomly mutagenized library .................... 49
3. Composition of the CA library ................................................... 51
Chapter 2. Evaluations of the CA library mutant fitness ........................... 52
1. Fitness of all library CA mutants ............................................... 52
2. Fitness of single residue CA mutants ....................................... 54
3. Locations of library mutations on the CA hexamer structure .... 61
Chapter 3. Biological basis for the genetic fragility of HIV-1 CA ............... 65
1. Analysis of conditionally nonviable (temperature-sensitive) CA
mutants ..................................................................................... 65
iv

2. Analysis of constitutively nonviable CA mutants ...................... 71
3. Evaluations of fragility by electron microscopy ......................... 75
Chapter 4. Analyses of CA library mutations in natural HIV-1 subtype B
populations ............................................................................................... 79
1. Occurrence of library CA mutations in an in vivo cohort ........... 79
2. Examination of ‘rare’ and ‘frequent’ mutations in primary cells 80
3. Correlation between fitness and variation in CA....................... 82
4. Summary of effects of random mutations in HIV-1 CA ............. 86
Chapter 5. Additional applications of the CA mutant library ..................... 89
1. Screen of CA library for resistance to MX2 restriction .............. 89
Chapter 6. HIV-1 IN and creation of a randomly mutagenized IN library to
better understand genetic robustness and fragility ................................... 94
1. Introduction to genetic robustness in HIV-1 IN ......................... 94
2. Comparison of IN and CA variability in vivo ............................. 96
3. Creation of the randomly mutagenized IN library ..................... 98
4. Composition of the IN library, and comparison with the CA
library ........................................................................................ 98
Chapter 7. Evaluations of IN library robustness and comparison
with CA ................................................................................................... 101
1. Fitness of single residue IN mutants ...................................... 101
2. Distribution of IN fitness and divergence with CA fitness ....... 106
3. Structural analyses of IN fitness on an intasome model......... 109
Chapter 8. Other functional impacts of IN mutations .............................. 113
1. Characterization of IN mutant phenotypes by western blot .... 113
2. Mapping of IN mutations with functional disruptions on an HIV-1
intasome model ...................................................................... 117
Chapter 9. Analyses of IN library mutations in natural HIV-1 subtype B
populations ............................................................................................. 120
1. Occurrence of library IN mutations in an in vivo cohort and
comparison with CA................................................................ 120
2. Mapping of correlations between fitness, in vivo frequency, and
variability on an HIV-1 intasome model .................................. 122
3. Summary of effects of IN mutations and comparison with effects
of CA mutations ...................................................................... 127
IV. DISCUSSION ............................................................................................... 130
The extreme genetic fragility of HIV-1 CA .............................. 130
v

Uneven mutational robustness of HIV-1 IN ............................ 144
Summary of HIV-1 IN and CA robustness and associated
implications ............................................................................. 152
V. REFERENCES .............................................................................................. 155

vi

LIST OF FIGURES
Figure 1. Retrovirus family phylogeny ................................................................... 2
Figure 2. Illustration of the retrovirus lifecycle ....................................................... 4
Figure 3. Organization of the HIV-1 viral genome ................................................. 8
Figure 4. Comparisons of viral mutation and evolution rates .............................. 12
Figure 5. Viral networks and their dynamics in hosts .......................................... 14
Figure 6. Lethal mutagenesis and the survival of the flattest .............................. 18
Figure 7. Diagram of HIV-1 assembly ................................................................. 21
Figure 8. HIV-1 CA structures ............................................................................. 23
Figure 9. Overview of HIV-1 IN, the intasome, and integration ........................... 29
Figure 10. Generation and composition of the CA mutant library ........................ 50
Figure 11. Fitness effects of all CA library mutants ............................................. 53
Figure 12. Fitness effects of single residue mutations in the CA mutant library .. 59
Figure 13. Changes in hydrophobicity or molecular weight are not primary
determinants of fitness ........................................................................................ 60
Figure 14. Linear distribution of fitness effects of single residue CA mutations .. 63
Figure 15. Mapping of CA fitness to the CA hexamer structure .......................... 64
Figure 16. Conditionally viable (ts) CA mutants display defects only when
assembled at a nonpermissive temperature........................................................ 68
Figure 17. All conditional (ts) CA mutants display reductions in extracellular
particle yield at the nonpermissive temperature .................................................. 69
Figure 18. The conditional (ts) CA mutant reduction in particle yield is protease
dependent............................................................................................................ 72
Figure 19. Most constitutively nonviable CA mutants display attenuated particle
formation.............................................................................................................. 74
Figure 20. Electron microscopic analysis of particle formation by conditionally
nonviable CA mutants ......................................................................................... 76
Figure 21. Electron microscopic analysis of particle formation by constitutively
nonviable CA mutants ......................................................................................... 78
Figure 22. Analysis of CA library mutations in natural HIV-1 subtype B
populations .......................................................................................................... 81
Figure 23. ‘Rare but fit’ CA mutants are indistinguishable from frequently
occurring fit mutants in primary cells ................................................................... 83
Figure 24. Correlation between CA fitness and natural variation ........................ 85
Figure 25. Summary of the effects of random mutations in HIV-1 CA ................. 88
Figure 26. Screening of CA library mutants for resistance to Mx2 ...................... 91
Figure 27. CA mutant residues conferring Mx2 resistance typically occur in
surface exposed regions of the CA hexamer ...................................................... 93
Figure 28. Comparison of naturally occurring variation in HIV-1 IN and CA ....... 97
Figure 29. Generation, characterization, and comparison of the IN and CA
randomly mutagenized libraries........................................................................... 99
Figure 30. Mutational fitness in IN and CA is not definitively determined by
changes in hydrophobicity or molecular weight ................................................. 105
vii

Figure 31. Distributions of mutational fitness effects in IN and CA .................... 108
Figure 32. Comparison of linear fitness distributions throughout IN and CA
sequences ......................................................................................................... 110
Figure 33. Mapping of IN mutant fitness on an HIV-1 intasome model ............. 112
Figure 34. Analyses of the robustness of IN mutants by western blot............... 114
Figure 35. Localization of nonviable IN mutants affecting particle production in
the intasome ...................................................................................................... 118
Figure 36. Nonviable IN mutants disrupting IN expression in virions are also
highly localized to IN subunit interfaces ............................................................ 119
Figure 37. Occurrence of library IN and CA mutations in natural HIV-1 subtype B
populations ........................................................................................................ 121
Figure 38. Residue surface exposure is a determinant of fit IN mutant frequency
in vivo ................................................................................................................ 124
Figure 39. HIV-1 IN natural variability is highly correlated with residue surface
exposure ............................................................................................................ 126
Figure 40. Diverse fates for random mutations in HIV-1 IN and CA .................. 129

viii

LIST OF TABLES
Table 1. Fitness measurements for viable HIV-1 CA mutants............................. 56
Table 2. Nonviable HIV-1 CA mutants................................................................. 57
Table 3. Summary of CA mutant viability by CA region ....................................... 62
Table 4. Fitness measurements of viable HIV-1 IN mutants ............................. 103
Table 5. Nonviable HIV-1 IN mutants ................................................................ 104
Table 6. IN mutant phenotypes by region.......................................................... 107
Table 7. Opposing frequencies of fit IN mutants in vivo ................................... 123
Table 8. Comparison of the robustness/fragility of HIV sequences ................... 131
Table 9. Comparison of the robustness/fragility of other viral sequences ......... 133
Table 10. Comparison of the robustness/fragility of viral genomes ................... 134
Table 11. Robustness/fragility measurements in nonviral proteins ................... 135

ix

I. INTRODUCTION
Retroviridae and human immunodeficiency virus-1 (HIV-1)
The impact of retroviruses in the modern era has been tremendously
broad and polarized, causing both global pandemic and also contributing
revolutionary biotechnology. While not formally named until 1974, the retrovirus
family had been characterized and implicated in numerous vertebrate diseases
since the 19th century [1,2]. After the early recognition of Bovine leukosis and
Jaagsiekte in sheep, key investigations of oncogenic retroviruses in chickens,
including Rous sarcoma virus (RSV), contributed to Temin’s proviral hypothesis
in 1964, which was based on his observations that RSV particles containing RNA
make a DNA copy that is integrated into the host chromosome [2,3,4]. The
ensuing discovery of reverse transcriptase (RT) in 1970 permitted definition of
the two distinguishing characteristics of retroviruses, the reverse transcription of
the single stranded RNA (ssRNA) genome to yield double stranded DNA
(dsDNA), and the subsequent integration of the dsDNA into host cell
chromosomes [5,6].
Concordant with these defining features, classification of retrovirus genera
is assigned based on phylogenetic analyses of the highly conserved RT
sequences (Figure 1). As Figure 1 indicates, retroviruses are also broadly
divided by the organization of their genomes into two categories, simple or
complex [7,8,9]. The simple retroviruses, which include gamma-retroviruses,
alpha-retroviruses, beta-retroviruses, and epsilon-retroviruses, are comprised,
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Figure 1. Retrovirus family phylogeny. Classification of retroviruses based on reverse
transcriptase sequence. Relevant retrovirus abbreviations discussed in the text. Figure adapted
from [2].
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primarily, of just three major structural genes. These include: gag, the
polyprotein which organizes the assembly of viral particles, pol, which contains
the required viral enzymes for reverse transcription (RT), viral genome integration
(integrase), and particle maturation (protease, pro, which occurs in a separate
open reading frame in beta- and delta-retroviruses), and env, which encodes the
surface and transmembrane portions of the viral envelope. Complex
retroviruses, on the other hand, contain the same three essential structural
genes, but typically include additional accessory or regulatory proteins, which are
often generated from multiply spliced transcripts.
Despite any differences in genome classification, there are other
commonalities amongst retroviruses. All retroviruses are enveloped,
nonsegmented, single-stranded, positive sense RNA viruses. Retroviruses are
also comparatively small in size, with genomes typically ranging from 7-13 kb,
and particles that are generally 80-120 nm in diameter. Furthermore, all retrovirus
genomes, aside from containing gag, pol, and env, are flanked on either end by
long terminal repeats (LTRs), which contain essential promoter, poly A signal,
and TATA components, and through their repeating nature, also help to ensure
proper reverse transcription.
Retroviruses also share a common life cycle (Figure 2). To summarize
briefly, viral entry (Figure 2A) initiates with the engagement of the retroviral
envelope with the specific host cell receptor(s), which triggers membrane fusion
at the plasma membrane, or, less frequently, fusion with endosomes.
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Figure 2. Illustration of the retrovirus lifecycle. (A) Steps in the lifecycle that occur during and
after viral entry. These steps include binding of the retrovirus to the host cell receptor, membrane
fusion with the plasma membrane (or with endosomes), release of the viral core and subsequent
uncoating, reverse transcription, entry through the nucleus, and finally, integration of the viral
DNA into the host genomic DNA. (B) Steps in the lifecycle corresponding to assembly and exit of
newly made viral particles. These steps include transcription by RNA polymerase II, splicing and
export of viral RNA from the nucleus, translation of the viral proteins, RNA packaging and Gag
assembly, budding, and release from the cell membrane, and finally, virus maturation. Figure
adapted from [10].
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Subsequent entry of the viral core into the host cell cytoplasm is followed by the
disassembly, or uncoating, of the viral core, after which the reverse transcription
complex (RTC) forms, and the ssRNA is reverse transcribed. The newly
synthesized dsDNA genome traverses the cytoplasm and forms a preintegration
complex (PIC), which permits nuclear entry. Subsequently, the viral dsDNA is
integrated into the host genomic DNA to yield the provirus, a process that will
later be described in far greater detail. To begin the formation of new retroviral
particles (Figure 2B), the promoter in the U3 region of the 5’ LTR engages the
error-prone RNA polymerase II for transcription. Viral RNA transcripts are then
spliced, as necessary, and escorted out of the nucleus, often with the aid of
accessory proteins. Some of the exported transcripts are translated as viral
proteins or polyproteins that are prepared for Gag assembly, while the remaining
full-length RNA transcripts are packaged for inclusion in new particles. As Gag
assembly and multimerization completes and viral budding begins, the
endosomal sorting complexes required for transport (ESCRT) network of proteins
are recruited to aid in the scission and release of the particle from the cell
surface. Finally, cleavage by the viral protease ends the life cycle with the
formation of a mature retroviral particle. (Basic retroviral characteristics and life
cycle reviewed in [9,11,12,13,14]).
Among the retroviruses, one has become the overwhelming focus of
intense research. Human immunodeficiency virus-1 (HIV-1) is one of the
deadliest human scourges the world has experienced, as infection typically
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results in acquired immunodeficiency syndrome (AIDS), which is responsible for
the deaths of an estimated 36 million people [15,16]. As of 2012, a further 35.3
million individuals were currently living with HIV, indicating that the clinical impact
of the virus remains tremendous, particularly as effective antiretroviral therapies
are accessible to just 34% of individuals in the middle- and low-income countries
where most infected individuals reside [15], and because vaccine strategies have
thus far proved challenging [17,18]. Overall, this is a relatively modern burden,
as the first indications of AIDS appeared in 1981![19,20], and the determination of
HIV-1 (often referenced as HTLV-III in the mid 1980s) as the causative agent of
AIDS followed in 1983-1984 [21,22,23]. The origins of the AIDS pandemic,
caused by the HIV-1 group M lineage, arose from a single cross-species
transmission from simian immunodeficiency virus (SIV) in chimpanzees (Pan
troglodytes troglodytes with SIVcpz) that occurred in southeastern Cameroon
around 1910-1930 and spread around Kinshasa [20,24,25,26]. However, several
additional HIV-1 transmission events between humans and other primates have
occurred, including non-pandemic HIV-1 group N and perhaps O lineage
transmissions from SIVcpz, HIV-1 group P lineage transmission from gorillas
(SIVgor), and a related cross-species transmission from sooty mangabeys
(SIVsmm) is now known to be the source of HIV-2 [20,24,27,28].
Notably, HIV-1, which will form the focus of the research discussed herein,
is a lentivirus, along with HIV-2 and primate SIVs (Figure 1). Additional
nonprimate lentiviruses are divided into four other groups: ovines-caprines,
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bovines, felines, and equines. Lentiviruses derive their name (slow, lentus-) from
their long incubation periods, and share many additional features, including
chronic and persistent viral replication, macrophage tropism, destruction of
specific hematologic or immunologic cells, the inclusion of accessory genes in
the genome, neurologic manifestations, and periods of latency [9,29,30].
Lentiviruses are also characterized by a common morphology, including a viral
core with a unique cone or cylindrical shape [9]. While lentiviruses are not
directly oncogenic like many pathogenic retroviruses, the immune disorders they
induce can result in oncogenic disorders, such as Kaposi’s sarcoma or
lymphomas [31,32].
As is true for other primate lentiviruses, the primary host cell receptor for
HIV-1 is CD4, and this significantly limits the tropism of the virus, as CD4
expression is generally restricted to macrophages, dendritic cells, and helper Tcells [33,34]. In fact, the slow decline in the population of CD4+ cells over the
course of HIV-1 infection contributes to, and defines, the hallmark HIV-1-induced
immunodeficiency that is AIDS [35]. In addition to CD4, the HIV-1 surface
envelope (gp120) must also bind one of two co-receptors, either chemokine
CXCR4 or CCR5 [36,37,38,39]. While most transmitted viruses initially utilize
CCR5 (R5-tropic), over time many switch to using CXCR4 (X4-tropic), in a
manner linked to disease progression [40].
Not surprisingly, many of the other defining features of HIV-1 involve its
unique viral genome (Figure 3), which is just 9-10kb in size. In addition to the
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Figure 3. Organization of the HIV-1 viral genome. Illustration of the open reading frames
comprising HIV-1. Sizes of proteins are not to scale. Figure adapted from [41].
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three structural proteins common to all retroviruses, Gag, Pol, and Env, the HIV-1
genome also includes two regulatory proteins essential for viral replication, Tat
and Rev, as well as four accessory proteins, Nef, Vif, Vpu, and Vpr, that can
modulate viral replication and affect pathogenesis in vivo. As the nature of the
work discussed in this thesis includes detailed analyses of the capsid (CA)
protein, which is part of Gag, and the integrase protein (IN), which is part of Pol,
these polyproteins will be reviewed in far greater detail in separate introductory
sections, but basic functions of the other proteins will be summarized. Env is
similar to the general retroviral envelope previously described, and consists of
surface, trimeric gp120, which elicits considerable virus-neutralizing antibody
responses, as well as transmembrane, trimeric gp41 [42,43]. The regulatory
protein Tat is primarily involved in nuclear transactivation of the LTR by
interactions with TAR sequences, and helps ensure proper activation and
elongation of viral genome transcription [44,45]. Both Tat, and the other
regulatory protein, Rev, are encoded by multiply spliced mRNAs [16]. Rev is
involved in regulating viral mRNA expression; it binds the Rev response element
(RRE) located in env and impacts nuclear export of either unspliced or singly
spliced RNAs [46,47].
One of the common features amongst the HIV-1 accessory proteins is
their capacity to act as adapter proteins, as they often bind other host cellular
complexes in order to target host proteins (frequently antiviral) for degradation,
generally in an ubiquitin-dependent fashion [48]. To this end, Vif, the viral
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infectivity factor, partners with cellular proteins (Cul5, elongins B and C, and
Rbx1) to promote the degradation of antiviral factor APOBEC3G (as well as
APOBEC3C, 3F, and 3H) [49,50,51,52]. Similarly, viral protein U (Vpu) aids
virion release through both its interactions with the restriction factor tetherin, in a
fashion causing tetherin degradation, and through its contribution to the
degradation of CD4 [53,54]. While the Vpr protein does not target a known
restriction factor for degradation, it has been speculated that this is likely, and Vpr
has very recently been suggested to target the host SLX4 complex to promote
arrest of the cell cycle in the G2/M phase as well as escape from innate immune
sensing [55]. Vpr may additionally be involved in the activation of transcription,
induction of cell death, and enhancement of RT fidelity [48,56]. The final HIV-1
accessory protein, negative factor (Nef), despite its misnomer labeling, is
reported to be involved in an increasingly large number of functions that primarily
enhance infectivity, alter replication, and delay immune clearance, but it is not
essential for viral replication. Nef’s wide-ranging roles in HIV-1 are known to
impact: signaling transductions pathways, host major histocompatibility complex1 (MHC-1) and CD4 and other protein expression, antigen presentation, cellular
trafficking, and survival of cells [57,58,59].
These descriptions of retroviruses and HIV-1, while basic, provide a
context necessary for understanding the subsequently described concepts and
experiments.
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Genetic robustness and fragility
One of the most remarkable features of HIV-1, and other RNA viruses, is
their strikingly high mutation rate. As Figure 4A demonstrates, the mutation rate
is higher for RNA viruses than for any other biological entity, with the exception of
one documented example of a viroid [60,61]. Furthermore, additional evidence
has shown that the mutation rate for ss(+)RNA viruses like HIV-1 is considerably
higher than for other RNA viruses, or DNA viruses for that matter (Figure 4B)
[62]. Given the neutral theory of molecular evolution, which postulates that the
mutation rate is the sole determinant of the rate of evolution [63], as well as the
adaptation theory [64,65,66], which also considers mutation rates to be central to
evolution rates, it is perhaps not surprising that ss(+)RNA viruses have also been
shown to have higher rates of evolution than other viruses (Figure 4C) [62]. In
fact, the HIV-1 genome has previously been estimated to evolve approximately
one million times faster than mammalian DNA [67,68].
Examination of viral mutation rates and evolvability is of importance in the
context of HIV-1 and RNA viruses on several fronts. Mutation rates have already
been determined to impact everything from pathogenesis in RNA viruses [69,70],
to drug resistance patterns [71,72], antiviral therapy success [73,74], efficacy of
vaccines [75,76], and the emergence of new pathogens [77,78]. However,
despite the simplicity of the neutral theory of molecular evolution, directly
equating mutation and evolution rates is unrealistic given the complex
environments in which these rates occur.
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Figure 4. Comparisons of viral mutation and evolution rates. (A) Evaluation of mutation
rates, as compared to genome size, for various biological entities. (B, C) Mutation (B) and
corresponding evolution (C) rates, as indicated, for the various major virus groups (as defined by
the Baltimore classification). Points are indicative of individual viruses. Figure adapted from [61]
and [62].
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To better understand this environment and the interplay between mutation
and evolution, it is helpful to conceive of viral populations as mutant networks
(Figure 5A). HIV-1’s use of error-prone reverse transcriptase and nonproofreading RNA polymerase II provides characteristic low-fidelity replication,
similar to other RNA viruses, and results in a mutation rate for HIV-1 of
approximately 1.4-3.4 x 10-5 mutations/nucleotide/cycle [79,80]. This, combined
with the large population size typical of HIV-1, has been suggested to mean that
every single point mutation, and some double mutation combinations, could
theoretically be produced during each replication cycle in an infected individual
(thus nearly every 1-2 days [81]), leading to an extremely genotypically diverse
population over time [82]. However, previous work has already determined that,
in addition to high mutation rates, RNA viruses also have comparatively low
tolerance to mutation [83]. Therefore, within the framework of a mutant network
(Figure 5A), some of the randomly introduced mutations will maintain a fitness
level, or replication competency, which is comparable to the parental sequence
(illustrated by red circles), while many others will have moderate (green circles)
or severe (gray circles) fitness defects. In this way, error-prone replication
proceeds as an exploration of available sequence space, and large populations
make for rapid, moderately low-risk travel through this space.
Still, not all entities, or RNA viruses for that matter, can tolerate mutation to
the same extent. Thus, the term genetic robustness can be employed to
describe a biological entity’s capacity to maintain function in the face of mutation
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Figure 5. Viral networks and their dynamics in hosts. (A) Schematic demonstrating how
mutations (colored triangles) are acquired from the consensus sequence (gray line) due to the
characteristic low-fidelity replication in RNA viruses. The population network indicates how RNA
virus populations can be illustrated as networks with genetic variants (colored circles) of differing
fitness that are linked by mutational pathways. (B) Illustration of how viral networks shown in (A)
might behave when under selection in a natural host. The center diagram shows the initial viral
population, and variants are indicated by circles (colored by fitness) connected by the network
(black lines). Overall, an indication is given of how robustness might be impacted by: differences
in host immune pressures (Host A vs. Host B), the presence of a restriction factor, or replication
in diverse tissues. Figure adapted from [82].

14

[84,85]. More robust proteins or organisms can tolerate higher mutation rates,
while less robust, or fragile, proteins or organisms are more intolerant of mutation
and are likely to lose function or to be driven to extinction by high mutation rates.
Determining genetic robustness typically involves quantification of mutational
fitness effects for individual mutations, in comparison with wild type fitness.
Generally, at least in the case of viruses, this is achieved by the introduction of
random point mutations into the genome and the subsequent measurement of
the mutation’s effect on replicative efficiency [86,87,88]. However, it is also
possible to more indirectly measure robustness of viruses by quantifying their
sensitivity to nucleoside analogues that artificially increase mutation rates [74,89].
In both cases, (subjectively) large mutational fitness effects are indicative of
fragility, while smaller fitness effects suggest robustness. In this way, robustness
can be calculated for whole entities, such as entire RNA virus genomes, or for
smaller segments such as proteins or domains. However, it is expected that
measurement of robustness for large entities like whole genomes may mask the
variation in robustness that occurs amongst individual proteins or regions within
that genome, in accordance with the specific functions of the individual proteins
or domains.
At present, there are no known absolute determinants of an entity’s
genetic robustness. Instead genetic robustness of an entity like HIV-1, or its
proteins, likely depends on a variety of specific characteristics, primarily
concerning individual functions and the natural host environment.
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Correspondingly, the robustness of either distinct viruses, or proteins or domains
within a virus, can vary widely, as the extreme robustness of the HIV-1 LTR, in
which data indicated that 100% of point mutants maintained WT-like levels of
infectiousness![90], and the relative fragility of HIV-1 protease![91], in which just
46% of mutants maintained viability, illustrate. To this end, it has been
previously theorized that proteins that perform multiple or complex functions that
are highly dependent on structure, such as enzymes (like protease), should tend
to be more genetically fragile and display greater sequence conservation than
those that do not [92]. At the same time, population genetics theory predicts that
robustness is more likely to be selected for when mutations rates are high, as it
should be advantageous [84,92]. Nevertheless, previous data has also shown
that robustness can vary even amongst whole virus genomes with high mutation
rates, as only 20% of single mutations in bacteriophage ΦX174 were considered
lethal [87], while more than twice as many, 41%, of point mutations in tobacco
etch potyvirus had the same effect [93].
As Figure 5B demonstrates, the host environment also has a large
influence on the available sequence space a population can utilize, and, thereby,
its overall robustness. Specific host features including interactions with
restriction factors or other cellular factors, tissue tropism, and other immune
pressures can impact the fitness of individual mutations, which in turn impact the
greater fitness landscape and the further exploration of sequence space [82]. In
the case of HIV-1, adaptive immune responses play a particularly significant,

16

hostile and changing environmental role. These immune responses can take the
form of antibodies that target proteins displayed on the surface of virions, or
cytotoxic lymphocytes (CTLs) that target epitopes in a number of viral proteins.
As a result, some viral proteins, even those that should exhibit genetic fragility as
a reflection of their complex or essential nature, are placed under strong
evolutionary pressure to diversify in sequence, despite fitness costs, in order to
evade adaptive immune responses. Under these conditions, otherwise fragile
proteins might evolve higher robustness. Ultimately, the pressures impacting
robustness can be narrowed to two broadly competing categories: those inherent
pressures imposing conservation of sequence in order to preserve specific and
essential functions, and opposing pressures to diversify sequence in order to
avoid a hostile host environment. However, the outcomes regarding any
potential trade-off between robustness and fitness are not established, so it is
unclear whether fitness, or acquisition of robustness, would constitute a dominant
selective force on a viral protein in the natural setting. It should be noted,
nevertheless, that initial examinations have suggested that, at least under certain
circumstances in viral populations, high robustness can be favored at the
expense of high fitness, indicating robustness may be the more potent selective
force [94,95,96].
Intriguingly, both theories and experiments concerning the evolution of
robustness have yielded a common observation: ‘survival of the flattest’
[95,97,98] (Figure 6). In further accordance with Sewall Wright’s 1932 adaptive
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Figure 6. Lethal mutagenesis and the survival of the flattest. Red indicates populations with
fast replication, but that are genetically fragile, while the blue shows ‘flat’ populations that have
slower replication, but are more robust. The panels on the left show populations with either high
or low mutation rates, and the right panels demonstrate the expected distributions of the two
types of populations under the different mutation conditions. When mutation rates are low, the
fitter population will always successfully outcompete the ‘flatter’ population. However, this can be
reversed when mutation rates are high, as the tops of the high narrow peak will display the
highest fitness, but the other population will have less variance in fitness due to its increased
robustness. Figure adapted from [96].
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landscape model [99], these results have indicated that at low mutation rates,
quickly replicating populations (in red, high fitness populations with little genetic
distance) are expected to always outcompete the slower replicating populations
(in blue, populations with more genetic distance) that have a low, flat peak and
higher robustness [96]. However, this situation can be reversed at high mutation
rates (Figure 6, bottom panels), when the flatter population with less variance in
fitness may be more adaptive. Consequently, for HIV-1, with its high mutation
rate, a flatter, more robust population with greater genetic variance might be
expected to be favored over more fit but fragile populations.
At the same time, a number of studies, using either mutagenic nucleoside
drugs or variant RNA-dependent RNA polymerases, have shown that the
mutation rate in RNA viruses is extremely close to a catastrophic error rate that
would lead to extinction [100,101,102], indicating there may be some degree of
fragility in these populations. These ‘lethal mutagenesis’ studies have sought to
determine the threshold at which the mutation rate becomes biologically
intolerable and viral infectivity is eliminated. From a therapeutic point of view,
examination of lethal mutagenesis for HIV-1 offers great potential as an
alternative to antiretroviral treatments susceptible to drug resistance [73]. This is
especially true given that natural hosts contain their own source of
hypermutagenesis in APOBEC3G (normally counteracted by Vif)![103,104,105].
Hence, examination of the genetic robustness or fragility of HIV-1 and its
components may contribute to therapeutic vaccine and drug development efforts
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not only through the revelation of regions remarkably sensitive to mutation, but
also through discovery of how close HIV-1 may already be to its own error
catastrophe.
HIV-1 capsid
As previously mentioned, evaluation of the robustness of whole viral
genomes can mask significant variability amongst proteins or domains within, in
accordance with specific functions or host pressures. For this reason, evaluation
of a single essential protein in HIV-1, such as capsid (CA), may provide a more
thorough, albeit localized, representation of genetic robustness and its causes
and consequences. Capsid is a particularly appropriate protein in which to
measure robustness as it experiences competing needs to both preserve
function, yet diversify sequence, in an acute manner. As a critically important
protein, it is placed under intense selective pressure to maintain its structure and
perform several functions. Conversely, as a highly expressed, immunologically
visible protein, CA also assumes a competing pressure to diversify its sequence,
and it is unclear how these competing pressures might impact the protein’s
genetic robustness.
Among the unique features of HIV-1 CA are its multifunctional nature and
its presence in different structural orientations—it exists as both a domain within
the Gag precursor polyprotein during particle assembly, and as an autonomous
protein in mature virions (Figure 7) [11,106,107]. As part of Gag, CA is
sandwiched between matrix (MA) at the 5’ end, and short spacer peptide 1 (SP1)
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Gag-Pro-Pol

!
Figure 7. Diagram of HIV-1 assembly. (A) Legend indicating the identity and corresponding
color of the respective proteins comprising Gag or Gag-Pro-Pol. Capsid is shown in the darker
green color. (B) Outline of the steps that occur during assembly at the plasma membrane and in
subsequent viral budding and maturation. (C) Sequential illustration of the HIV-1 Gag
polyprotein’s proteolytic cleavage. Image adapted slightly from [108].
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at the 3’ end (Figure 7A). Gag also includes nucleocapsid (NC), spacer peptide 2
(SP2), and p6, which follow SP1 sequentially, whilst Gag-Pro-Pol additionally
contains the viral enzymes (protease, reverse transcriptase, and integrase) at the
3’ end of Gag (Figure 7A) [108]. In the initial stages of virion morphogenesis,
Gag molecules assemble, largely through the targeting of MA, at the plasma
membrane, along with additional Gag-Pro-Pol molecules (Figure 7B), to drive the
formation of roughly spherical virions, which contain radially arrayed Gag
molecules that bud through the plasma membrane [109,110]. During and after
subsequent viral budding, protease is activated and catalyzes cleavage of Gag in
five positions (Figure 7C), causing extensive morphological transformations and
the transition from an immature to mature viral particle![14]. As a result, the
liberated CA protein forms a distinctive conical capsid that encapsulates the
nucleocapsid-genomic RNA complex [111,112].
Like all retroviral capsids, the 231 amino acid (aa) HIV-1 CA molecule is
composed of two domains: the N-terminal domain (NTD), which contains the first
146 aa, and the C-terminal domain (CTD), which contains the remaining 85 aa.
The structure of the NTD comprises an N-terminal β hairpin followed by 7 α
helices, while the CTD consists of 4 α helices and a final C-terminal unstructured
region of 11 residues (Figure 8B, 8C and 8D in white) [113,114,115]. In between
the NTD and CTD lies a small interdomain linker region (residues 146-150).
Other noteworthy regions in CA include the major homology region (MHR,
residues 153-172) of the CTD, which is a highly conserved 20 amino acid region
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Figure 8. HIV-1 CA structures. (A) A slab view illustrating an experimental map of CA hexamer
formation, with the CTD in blue, the NTD in green, and a red line outlining the hexamer. (B) A
pseudoatomic model of the full-length CA monomer. Individual helices and loops are labeled
accordingly. (C, D) External views of the CA hexamer, in which a single monomer is outlined in
white. (E) Stereoview of the complete CA fullerene cone, comprised of approximately 1,056
subunits, and including 12 pentameric declinations. The pentamer structures are shown in
yellow, while the hexamer NTD is in orange and the hexamer CTD is in blue. Figure constructed
with images from [116] and [117].
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found in all retroviruses [118] and the likely binding site of host protein ABCE1!
[119], and a loop (NTD residues 85-93) which binds the cellular protein
cyclophilin A (hereafter referred to as the cyclophilin binding loop) [120].
As will later become evident, the structure of CA is particularly relevant to
its robustness, and thus its components warrant further description. The mature
HIV-1 capsid includes ~1056 CA monomers arranged in a hexameric lattice
(Figure 8A, and 8E in orange/blue) interspersed with 12 pentameric declinations
(Figure 8E, in yellow) which allow the viral capsid to form a fullerene cone (Figure
8E) [111,117]. Within the hexameric lattice (Figure 8A, C, E), the NTD creates
the hexamer ring shape (Figure 8A, C in green, 8E in orange) while the CTD
forms the dimeric linkers that link neighboring hexamers (Figure 8A, C, E in blue)
[116,121]. Correspondingly, there are three primary protein-protein interactions
in the mature capsid lattice: NTD-NTD, CTD-CTD, and NTD-CTD. The NTD-NTD
hexamerization interface is mediated by a six-fold symmetric interface involving
helices 1, 2, and 3 (to form an 18-helix bundle) [116,122]. The homodimeric CTDCTD interface links the hexameric building blocks and occurs through a parallel
association at helix 9 (around residue 185), although other CTD regions likely
contribute to the stability of this arrangement [115,123]. Finally, the hexamer is
reinforced through stabilizing intermolecular NTD-CTD interactions, primarily
involving the extended side chains from CTD helix 8 which maintain interfaces
with NTD helices 3-4 (and the intervening loop) [123,124,125]. Protein
interactions in the relatively rare pentameric declinations (Figure 8E, in yellow)
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are similar to those found in hexamers, with only subtle rearrangements in the
subunit interactions [117]. Disruptions to any of the interaction interfaces are
likely to disrupt proper capsid assembly, causing irregularly shaped capsids and
less- or noninfectious particles [123]. Additionally, the dramatic differences
between the conformations of immature and mature capsid suggest the presence
of additional protein-protein interfaces and interactions not found in the mature
capsid, and if these were disturbed, would also be likely to negatively impact
assembly [110].
In addition to contributing a major structural role, CA determines several
other biological properties of HIV-1. For instance, HIV-1 capsid has been
demonstrated to be the key determinant that permits HIV-1 to infect non-dividing
cells [126,127]. Other work has identified capsid as having a number of genetic
or physical interactions with various host proteins, including karyopherin β
transportin-3 (TNPO3) [128], nucleoporin 153 (NUP 153) [129,130], nucleoporin
358 (NUP358)/RanBP2 [131], and cleavage and polyadenylation factor 6
(CPSF6) [132]. Moreover, the interactions between HIV-1 capsid and host
protein cyclophilin A are also known to influence nuclear import and subsequent
integration site selectivity, as well as replication efficiency, in a cell type
dependent manner [131,133,134,135].
Capsid is also a major target of intrinsic, innate, and adaptive immune
defenses. Intrinsically speaking, capsid has recently been shown to be a
determinant of HIV-1’s sensitivity to the antiviral factor Myxovirus resistance 2
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(Mx2) [136], an interferon-induced, dynamin-like GTP-ase that can inhibit early
steps of HIV-1 infection in vitro. Reports of CA residues affecting Mx2 restriction
of HIV-1 have thus far been limited to CA residues within the cyclophilin binding
loop (and one other residue, N57, previously reported to affect HIV-1 infection of
non-dividing cells [127]) [136,137,138], however the likelihood that other residues
within CA determine sensitivity to Mx2 will be further explored in the results
section. CA is also targeted by antiretroviral factor TRIM5α, and is thereby a
major determinant of its restriction capacities [139,140]. Alternatively, as a target
of the innate immune defenses, CA is believed to be detected by undefined
sensors in dendritic cells [141].
HIV-1 CA is also under pressure from adaptive immune forces
[142,143,144,145]. In particular, host human leukocyte antigen (HLA)-associated
CD8+ cytotoxic T lymphocyte (CTL) responses to HIV-1 infection are significant
determinants of viral control [146,147], and there is an association between Gagand capsid-specific CD8+ T-cell responses and the in vivo viral burden [148].
Moreover, the emergence of viral ‘escape’ mutations in CA has been shown to
result in higher viremia in infected patients [149,150]. However, CA escape
mutations often incur significant fitness costs, which may be subsequently
compensated for by secondary mutations in CA, or result in reversion when
immune pressure is lifted [144,150,151].
A large number of earlier studies have mutated HIV-1 capsid with the aim
of elucidating the importance of particular domains, regions, and residues in CA
functions. Such targeted mutagenesis studies have largely relied upon insertion
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[152], deletion [153], or alanine or proline scanning [154,155]. While certainly
informative of the impact a single residue mutation could have on infectivity, core
morphology, or the like, these studies are not necessarily predictive of the
phenotypes that might result from naturally-occurring mutations that arise through
errors during reverse transcription or from RNA polymerase II. In our CA
mutagenesis approach, we will attempt to utilize more unbiased means of
inducing mutation, on a far larger scale, and in so doing, measure the genetic
robustness of CA and determine it’s biological causes and implications. These
are, of course, deeply rooted in the many functions and interactions of HIV-1
capsid.
HIV-1 integrase
To establish whether any trends observed from evaluation of the genetic
robustness of HIV-1 capsid might be unique to CA, or a larger reflection of the
robustness of the entirety of HIV-1, it seemed prudent to evaluate the genetic
robustness of another important HIV-1 protein. HIV-1 integrase (IN), like HIV-1
CA, is a highly conserved, essential, multifunctional protein, and is the enzyme
responsible for the integration of the viral genome into the host chromosome.
Within the framework of the viral life cycle, IN functions just after reverse
transcription, and is responsible for two necessary catalytic activities, 3’
processing and DNA strand transfer. It has previously been hypothesized that
the requirements needed to fulfill enzymatic catalytic activities like these, which
involve adopting and changing tertiary structures in subtle, flexible ways, may

27

mean enzymes are particularly sensitive to mutation [92]. The relatively high
degree of conservation in integrase, especially within the protein’s catalytic core
domain [156], also suggests IN may be not be tolerant of mutation.
While the crystal structure for the functional HIV-1 IN unit, the intasome,
has not yet been determined, significant insight exists regarding the domain
structures and functions in the 32 kDa, 288 amino acid HIV-1 IN protein (Figure
9A). At the most N-terminal end, the roughly 49 amino acid N-terminal domain
(NTD) adopts a helix-turn-helix fold, contains a highly conserved HH/CC zinc
binding domain (at residues 12, 16, 40, 43, Figure 9A), and contributes to
stabilization, multimerization, and DNA binding [157]. The adjacent catalytic core
domain (CCD), residues 50-212 (also sometimes reported as 59-202), is
responsible for both 3’ processing and strand transfer reactions, and also
contributes to multimerization and both viral DNA (vDNA) and host target DNA
binding [158,159]. This domain adopts a RNase H fold, and contains a D, D(35)E motif that binds divalent metal ions, largely Mg2+ [159,160]. At the C-terminal
end, the C-terminal domain (CTD), which includes residues 213-288 (or 223270), adopts a beta barrel resembling an Src homology 3 (SH3)-type fold, is
significantly involved in binding to host cell target DNA, and like the other
domains, also contributes to multimerization [159,161,162]. Ultimately, the three
domains in each monomer come together to form a tetramer comprised of a
dimer of dimers, which, when bound to the vDNA, forms the intasome [163]
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Figure 9. Overview of HIV-1 IN, the intasome, and integration. (A) Organization of the HIV-1
IN protein, indicating the approximate individual domains, their sizes, and the notable elements
within. (B) First published model of the HIV-1 intasome, with the image on the left showing the full
IN tetramer. The right image indicates the IN dimer and the domains within. (C) Schematic of the
retroviral integration processes, indicating the retroviral nucleoprotein complexes formed during
the IN-mediated DNA cutting and joining of the DNA. Figure constructed with images from [164],
[159], [165].
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(Figure 9B). The publication of the crystal structure of the prototype foamy virus
(PFV) intasome has provided further insight into the possible arrangement of
HIV-1 IN’s three domains within the tetramer, and has suggested how the
domains might contribute to vDNA and host DNA binding [166,167].
Furthermore, the PFV crystal structure, and the knowledge it has conveyed, has
led to new, improved HIV-1 intasome models [164,168] (Figure 9B).
The catalytic activities of integrase begin within the confines of the reverse
transcriptase complex (RTC) in the host cell cytoplasm (Figure 9C). After
reverse transcriptase copies the single-stranded viral RNA genome into a linear
double-stranded DNA molecule that contains a copy of the LTR at each end,
multimeric (likely tetrameric) integrase binds the newly synthesized LTR ends to
form the retroviral intasome complex known as the stable synaptic complex
(SSC) [165,169] (Figure 9C). During the subsequent 3’ processing reaction, IN
processes each LTR end at a location adjacent to an invariant CA dinucleotide,
so as to yield CAOH 3’-hydroxyl groups, which will later serve as the nucleophile
in the second reaction [170,171]. This 3’ processing reaction results in an
intasome configuration known as the cleaved donor complex (CDC). At the
same time, the viral replication intermediate now has the capacity to initiate DNA
strand transfer activity, and this marks a transition in the viral nucleoprotein
complex nomenclature from the RTC to the pre-integration complex (PIC). Upon
nuclear entry and the location of a suitable target site on the host cell chromatin,
tetrameric IN uses the exposed 3’ oxygen atoms to cut phosphodiester bonds on
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opposing strands of the target DNA (tDNA), in a staggered fashion, and it also
simultaneously joins the viral DNA ends to the tDNA’s 5’ phosphates
[172,173,174] (Figure 9C). The initiation of the DNA strand transfer reaction, in
which the CDC engages the tDNA, leads to the formation of the target capture
complex (TCC), and the subsequent integration of the viral DNA 3’ ends results
in the formation of the strand transfer complex (STC). Finally, host cell enzymes
repair the unjoined viral DNA 5’ ends, to yield the fully integrated provirus.
Determination of these enzymatic functions of IN has often involved
mutagenesis of IN. Scanning and site-directed mutagenesis work has been
critical to demonstrating the structural and functional contributions of both whole
subunits and individual residues within IN [175,176,177,178,179,180,181].
Furthermore, deletion mutants of various subunits, or parts thereof, have also
proved individual domain contributions to both HIV-1 IN catalytic activities, and
initially indicated the likelihood that IN forms a functional multimer [182,183,184].
Overall, however, mutations in IN have typically been divided into two classes
[185]. Class I mutants are those that directly affect either of the enzymatic
activities of IN (which in turn, affect infectivity), while class II mutants reduce
infectivity at a stage other than integration. In some cases, class II mutants have
also been shown to yield virions with abnormal cores [186]. Despite the large
quantity of IN mutagenesis studies probing specific function, no study has
randomly or extensively mutagenized the entirety of HIV-1 integrase yet, nor has
any study sought to evaluate its genetic robustness.
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Mutagenesis of IN has also helped demonstrate interactions between IN
and its cellular co-factors. Like CA, IN is known to interact with a number of host
proteins, some of which are required for efficient levels of infectivity. Perhaps the
most important of these co-factors is the essential lens epithelium-derived growth
factor (LEDGF/p75), which helps direct integration into chromatin sites within
genes, or regions with active transcription units [187,188]. Certain mutations
within IN, particularly in the C-terminal region of the catalytic core domain, have
the ability to disrupt the interaction between IN and LEDGF and correspondingly
impact infectivity [189]. HIV-1 integrase is also believed to interact with IN
interactor 1(INI1)/hSNF5 [190], as well as the cellular co-factor transportin SR-2
(TRN-SR2, or TNPO3), a karyopherin which helps mediate nuclear import [191],
amongst other less confirmed interactions [192,193].
Despite its interactions with the cellular environment, and unlike HIV-1 CA,
HIV-1 IN does not appear to be the target of intense, or, rather, successful
immune responses. At present, there are no known intrinsic or innate immune
defenses that target IN. Furthermore, while certain human leukocyte antigen
(HLA)-associated CD8+ cytotoxic T lymphocytes (CTL) epitopes to CA can be
protective, and correlated with reduced viral loads, replication capacity, or non- or
delayed progression to AIDS [194,195], the same does not appear to be true for
integrase [148]. Integrase can be a target of CTL responses, including some
associated with protective HLA class I alleles [196,197,198], and individuals with
reduced viral loads can very occasionally show T-cell responses against
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integrase [199]. Nevertheless, more conclusive evidence suggests that there is
no substantial immune-driven attenuation of integrase during HIV-1 infection
[200].
As anti-retroviral treatments for HIV-1 have progressed, integrase has
become an increasingly important target of HIV-1 therapeutic treatment. In fact,
a multitude of integrase inhibitors targeting the individual integration steps have
been developed, and these can be divided into six general classes: DNA-binding
inhibitors, 3’ processing inhibitors, nuclear translocation/import inhibitors, strand
transfer inhibitors, gap repair inhibitors, and the allosteric inhibitors [156,201]. At
present, the integrase strand transfer inhibitors (INSTIs), raltegravir, elvitegravir,
and dolutegravir, have been the most clinically successful class of inhibitors
[165,202]. However, the susceptibility of these drugs to resistance mutations has
meant that the search for new integrase inhibitors continues [202]. Work has
increasingly focused on the allosteric integrase inhibitors (ALLINIs), which may
work by competing with LEDGF/p75 for binding to integrase, thereby disrupting
integrase assembly with viral DNA and inhibiting enzyme function [203].
Furthermore, recent work has shown that administration of a long-acting
integrase inhibitor can protect macaques from infection by a simian/human
immunodeficiency virus [204]. Evaluating the genetic robustness of HIV-1 IN
therefore seems a particularly worthy task, as it presents the possibility of
uncovering regions of vulnerability or fragility that could prove valuable to novel
inhibitors or other therapeutic treatments. Moreover, comparison of IN
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robustness with that of CA should reveal more about how the competing
pressures to maintain sequence for function preservation, and also to diversify
sequence to avoid immune pressure, might vie in different circumstances.
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II. MATERIALS AND METHODS
Plasmids
Throughout the described work, production of infectious HIV-1 was
achieved using derivatives of a proviral plasmid previously used in our laboratory,
pNHG (accession: JQ585717) [205]. Containing full-length HIV-1, with the
exception of Nef, which is replaced with EGFP, pNHG expresses NL4.3 GagPol
and HXB2 envelope (the remaining portions being previously derived from
pNL/HXB and R7/3/GFP [206,207]). All of the work done to construct the CA
mutant library and evaluate its genetic robustness was done with a derivative of
pNHG, pNHGcapNM (accession: JQ686832), created by Sam Wilson [208].
Almost identical to pNHG, pNHGcapNM differs only in that it contains three
additional restriction enzyme sites, NotI and MluI that roughly flank the capsid
protein, and a SpeI site that lies around the middle of capsid. These sites were
created through synonymous substitutions, with the NotI site added in matrix
approximately 36 nucleotides 5’ to capsid, while the MluI site lies within capsid,
approximately 12 nucleotides from its 3’ end.
Work done to synthesize and characterize the HIV-1 integrase mutants
was done with a similar derivative of pNHGcapNM, pNHGintBS. To create this
proviral plasmid the first required step was to eliminate the SpeI site in capsid of
pNHGcapNM. This was done by amplifying the region between the NotI and MluI
sites, using primers with overlapping sequence that eliminated the SpeI site in a
synonymous fashion (sense primer: 5’- CCA AGG GGA AGT GAC ATA GCA
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GGA ACT ACG AGT ACC CTT CAG GAA CAA ATA GG -3’ and antisense
primer: 5’-CCT ATT TGT TCC TGA AGG GTA CTC GTA GTT CCT GCT ATG
TCA CTT CCC CTT GG -3’). Using the overlapping PCR scheme, the two
products from a first round of PCRs (the NotI-antisense primer product and the
sense primer-MluI product) could be used as templates with external primers
incorporating the NotI and MluI sites in another PCR reaction, after which the
final PCR product was gel-purified and cloned back into pNHGcapNM. Next, it
was necessary to create the new BstBI and SpeI sites that could flank integrase.
Creation of the BstBI site was done using a similar overlapping PCR scheme,
with amplification of a region between MluI and EcoRI sites. Again, utilizing
synonymous nt substitutions to create the BstBI site (sense primer: 5’- GGT TGG
TCA GTG CTG GAA TTC GAA AAG TAC TAT TTT TAG ATG G -3’ and
antisense primer 5’- CCA TCT AAA AAT AGT ACT TTT CGA ATT CCA GCA
CTG ACC AAC C -3’), two products from a first round of PCRs (containing a
MluI-antisense primer product and a sense primer-EcoRI product) were weaved
together with external primers including the MluI and EcoRI sites. Following gel
purification of the final PCR product, it was cloned back into the pNHGcapNM
lacking SpeI, using the MluI and EcoRI sites. Addition of a new SpeI site was the
final step to completing pNHGintBS. Once more, the overlapping PCR scheme
was used, with amplification of the region between MluI and EcoRI sites.
Synonymous nucleotide substitutions were used to create the SpeI site (sense
primer: 5’- GGA TTA ACA CAT GGA AAA GAC TAG TAA AAC ACC ATA

36

TGT ATA TTT CAA GGA AAG C -3’ and antisense primer: 5’- GCT TTC
CTT GAA ATA TAC ATA TGG TGT TTT ACT AGT CTT TTC CAT GTG TTA ATC
C -3’), such that products from a first round of PCRs (containing the MluIantisense primer product and a sense primer-EcoRI product) were used as
templates that could be weaved together with external primers including the MluI
and EcoRI sites in a second reaction. The final PCR product was then gelpurified and cloned into the pNHGcapNM containing the BstBI site (and the
eliminated SpeI site in capsid) using the MluI and EcoRI sites. As a result,
pNHGintBS was created (from pNHGcapNM), so that a BstBI restriction site is at
the 5’ end 9 nt outside integrase (in reverse transcriptase) and a SpeI site is at
the 3’ end 15 nt outside integrase in Vif.
The final plasmid used in the described work is pNL4.3 Pr- (sometimes
referred to just as Pr-), which has also been previously used in our lab [209].
This plasmid is a derivative of pNL4.3 (NIH AIDS Research and Reference
Reagent Program, Catalog No. 114), in which protease is inactive, due to the
presence of a point mutation in the protease active site [209]. The capsid
mutants used in this plasmid were digested from pNHGcapNM and cloned
directly into pNL4.3 Pr- using compatible NotI and MluI sites found flanking
capsid in each plasmid.
Construction of CA and IN mutant libraries
Construction of the unbiased CA mutant library was completed by Sam
Wilson using a low fidelity PCR approach. The Genemorph II random
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mutagenesis kit (Agilent) was used with the following oligos: sense – 5’ –GTA
AGA AAA AGG CAC AGC AAG CGG CCG CTG - 3’ and antisense 5’ – CTT
GGC TC A TTG CTT CAG CCA AAA CGC GTG - 3’. The resulting PCR product
was cloned using a TOPO TA Cloning Kit and then plasmid DNA was extracted
from approximately ~1x104 pooled, insert-positive colonies. Following
sequencing of the amplicon from 20 clones, in order to obtain a preliminary
estimate of the mutagenesis frequency, the pooled plasmid DNA was digested
using NotI and MluI, and the pooled CA-library insert was subcloned into
pNHGcapNM (Figure 10A). The NotI and MluI digested proviral plasmid had
been prepared in advance and generated >200-fold fewer colonies when ligated
without insert than when ligated with insert. Additionally, representative
restriction digests indicated that aberrant restriction patterns, which could be
caused by recombination, occurred at a frequency of only 1-2% of clones.
Finally, proviral plasmid DNA was extracted from individual cultures derived from
1056 colonies and subjected to sequencing and further analysis. For the single
mutants listed in Tables 1 and 2, proviral plasmid DNA was freshly isolated, resequenced and analyzed by NotI and MluI restriction digest.
Creation of the IN mutant library was completed in a manner similar to that
done for the CA mutant library. As before, the Genemorph II random
mutagenesis kit (Agilent, Cat. No. 200550) was utilized, this time with the
following oligos precisely flanking IN: sense 5’ – GGA AAT GAA CAA GTA GAT
GGG TTG GTC AGT GCT GGA ATT CGA AAA GTA CTA – 3’ and antisense 5’ –
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GCT TTC CTT GAA ATA TAC ATA TGG TGT TTT ACT AGT CTT TTC CAT
GTG TTA – 3’, in several separate reactions with varying amounts of template
pNHGintBS (400-700 ng), in order to determine the template quantity providing
the optimal number of single residue mutants. Both the mutagenized PCR
products and the proviral plasmid pNHGintBS were then digested with BstBI and
SpeI, ligated, and cloned (Figure 29A). Cloning in pNHGintBS without insert
generated >500-fold fewer colonies than cloning with the mutagenized insert. To
ensure the appropriate mutagenesis frequency, preliminary amplicon sequencing
was done for approximately 285 mutagenized plasmid clones with varying
template quantities (400, 500, 600, or 700 ng). During subsequent production of
the library under the conditions yielding the highest number of single nucleotide
changes (400 ng template), DNA was extracted from individual cultures derived
from ~768 colonies. Amplicon sequencing then revealed which mutant clones
contained only a single amino acid mutation, and were suitable for inclusion in
the library. Final library proviral plasmid DNA was then freshly isolated for the
single IN mutants, and subjected to analysis by restriction digest using BstBI and
SpeI, at which point ~2% of clones were removed for evidence of recombination.
Cell lines and transfection
The 293T adherent human cell line was maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and
gentamicin. Suspension cell lines used in this work were maintained in Roswell
Park Memorial Institute medium (RPMI-1640), also supplemented with 10% fetal
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calf serum and gentamicin, and these included MT-4 cells and also a variety of
other MT-4 lines expressing species variants of the Mx2 protein (either human
(Hs) macaque (Mac), African Green Monkey (AGM), ovine, or canine). Those
MT-4s with variants of Mx2 were made by Sam Wilson and Idoia Busnadiego,
and were generated by transductions with modified LKO-derived lentiviral vectors
followed by selection with 2 μg/ml puromycin (Sigma). Expression of Mx2
variants in these cell lines was induced by overnight treatment with 125 ng/ml
doxycycline hyclate (Sigma), prior to viral challenge.
In transfection experiments, 293T cells were plated at 2.5 x 104 cells/well
in 96 well plates or 1.7 x 105 cells/well in 24 well plates. To measure the effects
of either CA or IN mutations, transfections were done the following day using 4
μg polyethylenimine (PEI, Polysciences) per μg of DNA, and either 100 ng (96
well plates) or 500 ng (24 well plates) of the WT (NHGcapNM or NHGintBS) or
NHGcapNM or NHGintBS mutant plasmids, or 500 ng of the pNL4.3 Pr- mutants
(all in 24 well plate experiments).
For the temperature-sensitive experiments, plates for all transfection
experiments were placed at 35, 37, or 39.5°C, as indicated, immediately upon
addition of the transfection mixture.
Primary cells
Peripheral blood mononuclear cells (PBMCs), CD4+ T cells, and
macrophages were isolated from buffy coats (from anonymous healthy donors,
purchased from the New York Blood Center) using a Ficoll gradient (with
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centrifugation at 1500 rpm, for 30 minutes, without brake). Bulk PBMCs were
isolated, and washed in RPMI by centrifugation three times. Primary CD4+ T
cells were extracted directly from buffy coats using negative selection via the
RosetteSep Human CD4+ T-cell enrichment cocktail (Stemcell Technologies,
#15062), also followed by centrifugation using a Ficoll gradient, as well as 2
RPMI washes. Macrophages were grown from a subset of the isolated PBMCs
by allowing the PBMCs to adhere to plastic plates and treating them with 100
ng/ml of granulocyte/macrophage-colony stimulating factor (GM-CSF) for 96
hours prior to infection. All primary cells were maintained in RPMI supplemented
with 10% FCS, L-glutamine, and penicillin/streptomycin. Activation of PBMCs
and CD4+ T cells was achieved by the addition of phytohemagglutinin (PHA) at 5
μg/ml for 72 hours prior to infection, with addition of 25 U/ml of interleukin-2 (IL-2)
at the time of infection.
Viral replication and infectivity assays
Relatively similar protocols were used to evaluate genetic robustness in
CA and IN through replication and infectivity assays. Therefore, unless
specifically ascribed to one protein, the referenced assays were used on both IN
and CA mutants.
In order to generate viral particles, 293T cells were transfected with the
indicated proviral plasmids and given fresh medium 16 hours later. At ~ 48 hours
post-transfection, cell supernatants were collected and filtered (0.22 μm). For the
single cycle assay, infectivity was measured using MT-4 cells that were seeded
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in 96 well plates at 4 x 104 cells per well and inoculated with a volume of filtered
supernatant that was equivalent to an MOI of ~1 for the WT viral clone. At 16
hours post-infection dextran sulfate was added at 100 μM in order to limit
replication to a single cycle, and cells were fixed in 4% paraformaldehyde (PFA)
48 hours after infection. Additionally, for temperature-sensitive mutants, the
same single cycle infectivity assay was used, but viral production (and
sometimes infection) occurred at 35, 37, or 39.5°C, as indicated in figure
legends.
For spreading replication assays, MT-4 cells seeded in 96 well plates at 2
x 104 cells per well were inoculated with a much smaller volume of supernatant,
equivalent to an MOI of ~0.01 for the WT viral clone, and fixed in 4% PFA at
around 80 hours post-infection. FACS analysis for all infectivity and replication
assays was carried out using a Guava EasyCyte instrument, and the percent of
infected cells was determined by the number that were GFP+.
Some of the temperature-sensitive CA mutations (used in Figures 16, 17,
and 18) that were originally detected in viability screens (as part of analysis of
Figure 11) were double or triple mutants, and are therefore not listed amongst CA
mutants evaluated for fitness in Tables 1 and 2. To isolate single residue
mutations responsible for the temperature-sensitive phenotype, CA mutants
encoding each of the following individual substitutions were generated from
double or triple mutants: S4C, L189M, I91F, Q6P, A78V, I15M, A78V, I15M,
A78T, S16T, T48A, S33C, A92V, I91N, D163E, I91V, I124T, M96T, R100S,
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Q112L, R132G, R167Q, M214L, AND K227I. All of these CA mutants, along with
other CA mutants identified in temperature-sensitive and viability screens, were
evaluated for the temperature-sensitive phenotype, and those 11 mutants with
the greatest effect were included in Figures 16-18.
For the CA mutant screen examining Mx2 sensitivity, purified plasmid DNA
was used from most CA mutants considered viable (>2% WT fitness) in the
single cycle infectivity assay, along with NHGcapNM. These mutants included:
I2L, N5D, I6T, M10I, M10L, Q13H, A14S, I15V, N21S, S33C, Q50H, N57S,
M68L, L69I, E75D, V83M, H87Q, H87R, P90T, I91T, I91V, Q95L, M96I, M96T,
E98D, R100S, N121I, R132G, S146C, T148I, S149C, S149G, I150V, L151I,
I153T, Y164F, R167Q, A177S, M185I, E187V, L190M, T200S, A204G, G208E,
A209V, L211I and T216A, and were used to transfect 293T cells in 24 well plates
as previously described. Supernatants were harvested 48 hours later, filtered,
and titrated onto doxycycline treated MT-4 cells encoding HsMx2, MacMx2,
AGMMx2, OvMx2 or CanMx2, in addition to MT-4 HsMx2 cells that had not been
doxycycline treated (as control). At 16 hours post-infection, infected cultures
were treated with dextran sulfate, so as to limit infection to a single cycle. Finally,
at 48 hours post-infection, all cells were fixed and subjected to flow cytometry,
such that infectious titers could be calculated by counting GFP+ cells.
Infections of primary cells necessitated different conditions. For the single
cycle infections of CD4+ T cells, 1 x 106 cells were inoculated using virus
generated from 293T cells, as described above, for the 11 rarely occurring ‘fit’ CA
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mutants described in Figure 22C, the WT virus, and 4 randomly selected
frequently occurring ‘fit’ CA mutants from Figure 22B (H87Q, I91V, E98D, T200S)
at an MOI of ~5, and were fixed in 4% PFA 36 hours later and subjected to FACS
analysis. For infection of macrophages, vesicular stomatitis virus (VSV)pseudotyped virus was generated in 293T cells for the same 15 mutants plus WT
virus, under transfection conditions in 24 well plates the same as previously
described, but with the addition of 50 ng of VSV-G. Macrophages were infected
at an MOI of ~4 and fixed for FACS analysis 72 hours later. For spreading
infection assays in PBMC, 1 x 106 cells were infected at an MOI of 0.1, and cells
were fixed at the time points shown in Figure 23C and then analyzed by flow
cytometry. The MOIs used for primary cells were reference values derived from
titrations on MT-4 cells.
Western blotting
Both virions, which were initially pelleted through 20% sucrose by
centrifugation (for 2 hours at 14000 rpm at 4°C), and cell lysates were
resuspended in SDS sample buffer and separated by electrophoresis on NuPage
4-12% Bis-Tris Gels (Novex). Proteins were then blotted onto nitrocellulose
membranes. For the CA mutant experiments, blots were probed with either a
primary anti-HIV p24 capsid antibody (183-H12-5C) or a primary anti-HIV MA p17
antibody (VU47 Rabbit anti-p17 [210]) and then probed with goat antimouse/anti-rabbit IRDye® 800CW secondary antibody (LI-COR Biosciences).
For the IN mutant characterizations, blots were probed with either primary anti-
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HIV p24 capsid antibody (183-H12-5C), primary anti-HIV INT-4 antibody ([211],
gift of Malim lab), or primary anti-clathrin heavy chain antibody (BD Biosciences,
#610499), whilst secondary probing was done using a goat anti-mouse antibody
(Thermo Scientific). A LI-COR Odyssey scanner was used to detect and quantify
fluorescent signals for all Western blots. A minimum of 3 separate Western blots
was produced for each temperature-sensitive mutant, including those in the
protease negative background, and representative blots are shown.
Structure analysis
Structural analysis of the HIV-1 capsid hexamer was done using
MacPyMOL, with RCSB Protein Data Bank (PDB) reference 3GV2.
Examinations using the HIV-1 intasome model were done with structure
coordinates provided by the authors of [168], also using MacPyMOL.
Analyses of solvent accessible surface area values for both the CA
hexamer and the IN intasome model were done using the UCSF Chimera
modeling system.
Thin-section microscopy
In order to prepare samples for thin-section electron microscopy, 293T
cells were seeded in 6-well plates at 0.8 x 106 cells per well, in duplicate.
Transfections were done the following day with the addition of polyethylenimine
to 2 μg of either the WT or mutant NHGcapNM plasmids (S33C, T48A, M96T,
Q112L, R132G, L189M, G60W, K25I, L52F or N195S) plus 0.5 μg of modified
human tetherin previously used in our laboratory (delGI, T45I that is resistant to
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antagonism by HIV-1 Vpu [212]) to enhance visualization of virions at the plasma
membrane. Immediately after addition of the transfection mixture, plates were
kept at either 37 or 39.5°C, as indicated. After 48 hours, the supernatant was
removed and the cells were fixed in a solution of 2% PFA, 2% glutaraldehyde.
One set of cells was then analyzed by FACS to compare the transfection
efficiencies (and these ranged from 23% for WT to 32% for L189M). The second
set of cells were fixed with 2.5% glutaraldehyde and 1% osmium tetroxide, and
stained with 2% aqueous uranyl acetate. The fixed and stained cells were then
harvested into PBS and pelleted through 1% SeaPlaque agarose (Flowgen) at
45°C. The agar was then set at 4°C and the cell pellets were cut into ~2 mm
cubes, which were dehydrated through a graded alcohol series and infiltrated
with TAAB 812 embedding resin. Following polymerization, thin sections (120
nm) were cut and examined in a JEOL 1200 EX II electron microscope. For each
sample, numbers of virus particles associated with 150 randomly selected cells
were counted. Thin-section EM analyses were done with the help of Dr. Frazer
Rixon.
Cryo-electron microscopy
In order to isolate virions for cryo-electron microscopy, 10 cm plates of
approximately 4 x 106 293T cells were transfected with 7 μg of the indicated
plasmids (NHGcapNM, R18G, K30N, G60W or M215V) using polyethylenimine.
Approximately 48 hours later, supernatant was collected and filtered, and virions
were pelleted by centrifugation at 14000 rpm through 20% sucrose. Pelleted
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virions from either WT or the CA mutants were then fixed in 10 μl of 2% PFA,
2.5% glutaraldehyde solution.
Subsequently, fixed aliquots of 3 μl of each sample were loaded onto
freshly glow-discharged c-flat holey carbon grids (CF-22-4C, Protochips, Inc.)
held at 4°C and 100% humidity in a Vitrobot vitrification robot (FEI). The grids
were blotted for 4 seconds prior to being frozen by plunging into a bath of liquid
nitrogen-cooled liquid ethane. Vitrified specimens were then imaged at a low
temperature in a JEOL 2200 FS cryo-microscope equipped with Gatan 626 cryostages. Finally, low dose (10 e/Å2), energy-filtered images (slit width, 20 eV)
were recorded on a Gatan ultrascan 16-megapixel charge-coupled-device
camera at a magnification of 50,000x. Cryo-EM analyses were done with the
help of Dr. Saskia Bakker.
Analysis of natural CA and IN variants
A cohort of 1,000 HIV-1 subtype B CA sequence isolates was obtained
from the Los Alamos HIV sequence database (www.hiv.lanl.gov). All sequences
were sampled from distinct infections between 1980 and 2009. In order to
minimize risks of sampling biases, multiple sequences from known transmission
clusters were excluded. Sequences with frameshift mutations or stop codons
that were likely to represent nonfunctional viruses or poor quality sequencing
were also excluded. Sequences were aligned using MUSCLE [213], and PERL
scripts were used to survey the genetic variation in the resulting sequence
alignment. An information-theoretic measure of diversity (Shannon’s entropy)
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[214] was applied to quantify the amount of amino acid variation at each capsid
position. Analysis of the natural variation in CA was done with the help of Dr.
Rob Gifford.
Similar to the cohort of sequences analyzed for CA, all HIV-1 subtype B IN
sequences from 1980 to 2013 were selected from the Los Alamos HIV sequence
database. Sequences with frameshifts, stop codons, or nucleotide ambiguities
(N or IUPAC code) were excluded from the dataset prior to randomly selecting
1000 sequences from distinct individuals and locations. As before, IN sequences
were aligned using MUSCLE, with the use of PERL scripts to determine the
number of mutations at each site in the alignment. Shannon’s entropy was used
to measure the amino acid diversity at each position within integrase. The
frequency of each amino acid was determined for each variable site. Analysis of
HIV-1 IN variants was done with the help of Dr. Joseph Hughes.
The hydrophobicity and molecular weight changes were also calculated for
all CA and IN library single mutants.

48

III. RESULTS
Chapter 1. HIV-1 CA and creation of a randomly mutagenized CA library
1.1 Introduction to surveying the robustness of CA through random
mutagenesis
HIV-1 CA is under acute competing pressures to both conserve sequence
to preserve function, and to diversify sequence to evade immune responses. To
evaluate how such pressures ultimately impact genetic robustness or any
potential trade-offs with fitness in an environment with a high mutation rate, we
utilized an unbiased mutagenesis method to generate a large library of randomly
mutagenized CA sequences that could simulate the natural process of random
mutation that occurs during HIV-1 replication. Analyses of the CA mutant library
uncovered a remarkable degree of genetic fragility in HIV-1 CA, and it is this,
along with its basis, in vivo correlates, and functional consequences, that will be
subsequently analyzed.
1.2 Creation of the CA randomly mutagenized library
Construction of the library of random HIV-1 CA mutants was completed by a
former postdoc in the Bieniasz lab, Sam Wilson, but was subsequently passed on
for the work described within this thesis. However, as the nature of its
construction is highly relevant to the subsequent experiments and analyses
herein, the generation will be briefly described.
To begin construction, a low fidelity PCR was approach was used, as
depicted in Figure 10A. In this method, sequences encoding capsid were
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Figure 10. Generation and composition of the CA mutant library. (A) Schematic illustrating
the replication competent proviral plasmid pNHGcapNM used for this study. The 717 bp amplicon
in Gag flanked by NotI and MluI restriction sites includes nearly all of CA, and a few amino acids
in MA. This amplicon was subjected to Genemorph II mutagenesis and subsequently subcloned
into pNHGcapNM. The conical capsid image was taken from PDB ID: 1VUT.
(B) Distribution of the number of nucleotide changes found in each library clone (including
sequences that occurred more than once). (C) Distribution of the number of amino acid changes
in each library clone (including sequences that occurred more than once, mutations in MA,
nonsense mutations, and frameshifts). (D) Pie chart depicting all resulting single amino acid
changes. SINGLE clones were those library mutants included in further experiments. The
remaining clones were discarded for the following reasons: STOP (mutation resulted in a stop
codon), MA (mutation occurred in the small fragment of MA included in the amplicon), FS
(frameshift), DUP (duplicate mutation of a clone already in the library). Creation of the library was
completed by Sam Wilson.
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amplified using Genemorph II, an unbiased error-prone PCR system, and cloned
using a TOPO TA cloning kit to yield a library with an estimated complexity of 1 x
104 clones. Subsequently, plasmid DNA was extracted from the pooled library
and digested, so that the mutagenized CA sequences were then inserted into the
replication competent proviral clone, pNHGcapNM, using NotI and MluI restriction
sites. As noted previously, pNHGcapNM (accession: JQ686832) encodes EGFP
in place of Nef, and will hereafter be referred to as the WT or parental virus for all
capsid mutagenesis work.
1.3 Composition of the CA library
Approximately 1000 individual colonies were then picked and proviral
plasmid DNA was extracted from individual mini-cultures. Each mutagenized CA
amplicon was then sequenced for every clone, and after the removal of clones
with failed sequencing reactions or whose chromatograms indicated the
presence of more than one template, 680 arrayed library proviral plasmids
remained. Evaluations of the library composition then revealed the distribution
of all nucleotide changes (Figure 10B), missense mutations (Figure 10C), and
nonsense or other mutations (Figure 10D). During the initial creation of the
library, conditions in pilot experiments were optimized to reduce the frequency of
both non-mutated and heavily mutated sequences in the library. As a result, the
most common mutation in the library was a single nucleotide or amino acid
substitution (Figure 10B, C, D).
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Chapter 2. Evaluations of CA library mutant fitness
2.1 Fitness of all library CA mutants
To determine the genetic robustness of CA, we examined the ability of the
680 CA library mutants to replicate. Replicative fitness was analyzed using a
spreading replication assay in which MT-4 cells were challenged with a small
volume of virus-containing supernatant harvested from WT or CA mutant
transfected 293T cells (equivalent to an MOI of ~0.01 for the WT virus). After
approximately 80 hours, and multiple rounds of the virus replication cycle, the
experiment was concluded once the WT virus had infected more than 50% of
cells. Each CA mutant’s replicative fitness was then expressed as the number of
cells that were infected (EGFP-positive), as a percentage of the number of cells
infected by the WT virus (Figure 11A, B). These viability screens were
conducted at two temperatures, 35°C (Figure 11A) and 39.5°C (Figure 11B) in
order to permit isolation of temperature-sensitive CA mutants that could facilitate
further characterization of the replication defects associated with CA mutations
(see below).
Not surprisingly, nearly all of the viral clones with WT CA sequence, or
containing silent mutations, replicated similarly to that of the WT pNHGcapNM
construct. This suggested that there was a low incidence with which defective
viruses were generated by cloning artifacts or silent mutations (Figure 11A, B).
More importantly, these analyses of CA library replicative fitness demonstrated
capsid to be extremely fragile, or intolerant to mutation. If the cut-off for being
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Figure 11. Fitness effects of all CA library mutants. (A) Viability of all CA mutant clones at
35°C (excluding nonsense, frameshift, duplicate and MA mutations), indicating how the number of
amino acid substitutions in CA affects fitness. Replication shown is the fraction of infected MT-4
cells (GFP+), as a percentage of the fraction infected by WT virus after a spreading replication
assay. (B) Viability of all CA mutant clones at 39.5°C, as in (A). (C) Distribution of mutational
fitness effects (DMFE) for all single amino acid CA substitution mutants at 35°C. (D) DMFE for all
of the single amino acid substitution mutants at 39.5°C. Data shown in (A) and (B) was measured
by Sam Wilson.
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viable is arbitrarily set at 2% of WT virus replicative fitness, only 35% of the 135
clones with single amino acid substitutions were viable at 35°C, and even fewer,
28%, were viable at 39.5°C. Given that the requirements for replication in an
infected individual may be more stringent than in highly permissive MT-4 cells,
these figures may even overestimate the proportion of mutants that are viable in
vivo. To this end, 2% of WT virus fitness is a rather generous cut-off to earn the
designation of ‘viable’. Increases in the number of amino acid substitutions
yielded even further reductions in viability; just 6% of the 125 clones with two
random amino acid substitutions were viable at 35°C, and this figure was only 3%
at 39.5°C. Accordingly, just 1 of 73 clones with 3 random amino acid
substitutions was viable, and none of the clones with either four or five random
substitutions could replicate at all.
It should be noted that the work involved in screening the entire CA library
for viability at 35°C and 39.5°C was done by Sam Wilson. However, his
involvement in the work ended at this point, and all further experiments described
herein were done independently, with the exception of some bioinformatics and
electron microscopic analyses requiring specialist assistance.
2.2 Fitness of single residue CA mutants
To better characterize the contributions of discrete residues to the genetic
fragility of HIV-1 CA, we next focused our attention on the subset of mutants with
unique single amino acid substitutions. These single mutants covered 102 (44%)
of the 231 residues in CA, and there were 33 CA residues for which there was
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more than one unique mutation. To evaluate robustness in more natural
conditions, two additional infectivity assays were performed at 37°C, utilizing only
the single residue mutants. In the first MT-4 spreading replication assay, just 40
mutant viruses (30%) exhibited at least 2% of parental virus fitness. These viable
mutants, and their corresponding fitness values can be found in Table 1, while
the longer list of the 95 mutants (70%) with less than 2% of WT fitness in the
spreading infectivity assay can be found in Table 2. In the second assay, single
cycle infectivity was measured by transfecting 293T cells with WT or CA mutant
proviral plasmids and measuring infectivity using a larger dose of virus
(equivalent to an MOI ~ 1 for the WT clone), and treating the MT-4 cells with
dextran sulfate 16 h post-infection, in order to limit replication to a single cycle.
Fitness in the replicative (spreading) versus the single cycle infectivity assay was
generally similar (Table 1), although most mutant viruses had slightly higher
fitness in the single cycle assay than in the spreading assay. This phenomenon
may be a product of the effect of transfection in the single cycle assay, in which
overexpression of viral proteins could mask any defects, as opposed to the
spreading infection assay in which lower gene expression levels may better
approximate those found in the natural environment. Alternatively, the multiple
rounds of replication permitted in the spreading assay may enhance the effect of
any defects in the single cycle assay.
Interestingly, the majority of the viable CA mutants still displayed
attenuated infectivity, as a remarkable 89% of single amino acid substitutions
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Table 1. Fitness measurements for viable HIV-1 CA mutants
Viable
HIV CA
mutant
I2L
N5D
I6T
M10I
M10L
M10V
Q13H
A14S
A14T
I15V
N21S
S33C
Q50H
E75D
V83M
H87Q
H87R
I91T
I91V
M96I
E98D
R100S
S146C
T148I
S149C
S149G
I150V
I153T
Y164F
R167Q
A177S
M185I
E187V
L190M
T200S
A204G
G208E
A209T
A209V
T216A

Location in CA
β-strand
β-strand
β-strand
β-strand
β-strand
β-strand
β-strand
Loop
Loop
Loop
Helix 1
Loop
Helix 3
Helix 4
Helix 4
Cyclophilin b.l.*
Cyclophilin b.l.
Cyclophilin b.l.
Cyclophilin b.l.
Loop
Loop
Loop
Loop
Loop
Loop
Loop
Loop
Loop
Helix 8
Helix 8
Loop
Helix 9
Helix 9
Loop
Helix 10
Helix 10
Loop
Loop
Loop
Helix 11

Single cycle
infectivity
a
(% of WT)
90
20
52
19
73.7
10.6
27.4
77.1
97.6
32.3
55.9
40.2
19.6
40.8
75.3
120.3
27.5
85.2
100.0
120.3
101.0
53.9
43.7
65.8
64.8
70.9
18.6
21.2
64.4
11.1
99.4
24.2
59.7
38.0
104.2
77.4
15.1
108.3
72.4
72.4

a

Spreading
infectivity
b
(% of WT)
65.6
5.2
56.9
2.9
27.0
16.2
5.8
80.7
86.6
13.6
46.6
47.8
3.1
22.1
64.8
92.0
2.5
76.9
82.8
92.0
63.4
42.5
34.0
37.3
73.7
30.3
3.1
4.7
30.6
5.9
37.3
2.5
47.4
32.6
90.4
89.0
3.8
94.3
84.3
37.5

Infectivity assay in which MT-4 cells were inoculated with supernatant from 293T cells (equivalent to
MOI = 1 for WT virus) that had been transfected with single residue CA mutant proviral plasmids.
Dextran sulfate was added 16h after infection to limit replication to a single cycle. Values are reported
as the percentage of the number of infected cells (GFP+) obtained with the WT virus.
b
Fitness measurement in which MT-4 cells were inoculated with supernatant from 293T cells
(equivalent to MOI = 0.01 for WT virus) that had been transfected with single residue CA mutant
proviral plasmids. Multiple cycles of replication were allowed over a 72-80 hr time period. Values are
reported as the percentage of the number of infected cells (GFP+) obtained with the WT virus.
* Abbreviation for cyclophilin binding loop.
Mutants were considered viable or infectious if they maintained 1/50 (or 2%) of WT infectivity in the
spreading infectivity assay.
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Table 2. Nonviable HIV-1 CA mutants
Nonviable
CA mutant
I2T
H12R
Q13R
S16P
R18G
N21Y
K25I
V26E
K30E
K30N
F32L
F32S
S33I
P34S
V36A
M39T
M39V
F40L
F40Y
L43I
G46R
P49L
L52F
N57S
V59A
V59M
G60W
Q63R
A65V
M66I
M66V
M68L
M68T
L69I
I73N
A77D
W80R
P90T
Q95L
Q95R
M96T
P99A
P99L
R100W
S102R
A105G
T110I
L111F

Location in
CA
β-strand
β-strand
β-strand
Loop
Helix 1
Helix 1
Helix 1
Helix 1
Loop
Loop
Loop
Loop
Loop
Helix 2
Helix 2
Helix 2
Helix 2
Helix 2
Helix 2
Helix 2
Loop
Helix 3
Helix 3
Helix 3
Loop
Loop
Loop
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Helix 4
Cyclophilin b.l.
Loop
Loop
Loop
Loop
Loop
Loop
Helix 5
Helix 5
Loop
Helix 6

Nonviable
CA mutant
E113V
I115K
I115L
I115T
M118L
M118V
H120P
N121I
I124N
V126A
I129M
I129T
Y130C
Y130H
R132G
G137E
L138I
M144V
L151I
L151Q
I153M
E159V
F161C
D163G
V165A
F168S
R173I
A174G
K182Q
W184L
W184R
T186A
L190S
A194V
N195S
I201N
L211I
E212D
M214L
M215V
A217V
Q219P
G220V
V221A
K227I
K227N
K227R

Location in
CA
Helix 6
Helix 6
Helix 6
Helix 6
Helix 6
Helix 6
Loop
Loop
Loop
Helix 7
Helix 7
Helix 7
Helix 7
Helix 7
Helix 7
Helix 7
Helix 7
Helix 7
Loop
Loop
Loop
Loop
Helix 8
Helix 8
Helix 8
Helix 8
Helix 8
Loop
Helix 9
Helix 9
Helix 9
Helix 9
Loop
Loop
Loop
Helix 10
Helix 11
Helix 11
Helix 11
Helix 11
Helix 11
Loop
Loop
Loop
Loop
Loop
Loop

Mutants were considered nonviable if they exhibited <2% of WT fitness in the spreading fitness
assay described in Table 1.
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caused a greater than 2-fold reduction in infectious virion yield. This observation,
in conjunction with the lack of mutants with replicative fitness greater than WT,
indicates that it may be difficult to improve upon the fitness of the parental CA,
which may already be near a fitness peak. Another way of analyzing the overall
robustness of the single residue mutants is to examine the distributions of
mutational fitness effects (DMFE). Previous work analyzing panels of RNA virus
single amino acid mutants have presented DMFE values that were bimodal in
nature, with substitutions typically resulting in either minor reductions in fitness or
lethality [86,87,93,94,95,96]. While this phenomenon was also true to some
extent for HIV-1 CA (Figure 11C at 35°C, Figure 11D at 39.5°C, Figure 12 at
37°C), the proportion of nonviable CA mutants was significantly larger than has
previously been reported [86,87,93,94,95,96], so that the proportion of viable CA
mutants was also significantly smaller than earlier reports, and the occurrence of
mutants with only minor fitness defects was also greatly reduced in the case of
HIV-1 CA (Figure 11C, D, Figure 12).
Assessments of Tables 1 and 2 reveal that different mutations at the same
residue in CA, such as I2, can sometimes result in highly variable fitness effects,
suggesting that the type of residue change is not entirely insignificant. However,
analyses of the mutant residues’ changes in hydrophobicity or molecular weight
for the entirety of the single residue mutant CA library did not reveal any general
associations with replicative fitness (Figure 13A, B). While some polar residues
appeared to be more sensitive to change, the lack of any overall or consistent
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Figure 12. Fitness effects of single residue mutations in the CA mutant library. Distribution
of mutational fitness effects (DMFE) for all single amino acid CA substitution mutants, using
fitness values obtained from the spreading infectivity assay at 37°C, as described in Table 1.

59

p=0.009
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Figure 13. Changes in hydrophobicity or molecular weight are not primary determinants of
fitness. (A) Evaluations of the effect of the type of residue change for all library mutations on
fitness (in a spreading replication assay). Letters indicate changes from the initial type of residue
to the mutated residue type, as indicated in the legend. Analyses of disparities between
conservative changes (i.e., polar (P) to polar (P)) and nonconservative changes (i.e., polar to
nonpolar (NP)) were performed for all scenarios, and all significant differences are indicated. (B)
Evaluations of the effect of the size of mutant residues’ molecular weight change on fitness (in a
spreading replication assay). Analyses between residue substitutions in which there was no
change in molecular weight and those with either increases or decreases in molecular weight
indicated no significant differences (significance determined using unpaired, parametric t-tests).
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patterns related to hydrophobicity changes suggests that types of residues
changes are not significant determinants of CA fitness. Moreover, inspection of
Tables 1 and 2 reveals that the position within CA was a far greater determinant
of a mutation’s fitness effect. Of the 231 residues in CA, 56.3% lie within CA’s 11
helices, 5.6% are in the N-terminal β-strand, 3.9% are in the cyclophilin A binding
loop, and the remaining 34.2% are in interhelical loops. Together, these figures
provide a context in which it is possible to summarize mutant fitness by region, in
order to indicate areas of particular genetic fragility in CA (Table 3, Figure 14).
Notably, there were distinct regions of relative robustness within CA, as 70-100%
of mutants retained some viability within the N-terminal β-strand, the cyclophilin
binding loop, and the interdomain linker region. In contrast, just 16% of mutants
in helices maintained viability, and an intermediate 39% of mutants retained
viability within the interhelical loops. More strikingly, all 25 mutations in helices 2,
5, 6, and 7 resulted in nonviability, suggesting these N-terminal helices are
particularly fragile. When these results are graphically represented such that the
fitness of each mutant is plotted against its position in the linear CA sequence
(Figure 14), it is even more apparent that regions of mutational fragility are nonuniformly distributed in CA, with mutations in NTD helices the most likely to result
in inactivation (Figure 14).
2.3 Locations of library mutations on the CA hexamer structure
When CA mutant fitness is displayed within the context of a capsid
hexamer structure (PDB: 3GV2, Figure 15A, B), amino acids corresponding to
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Table 3. Summary of CA mutant viability by CA region
Region
β-strand
Helix 1
Helix 2
Helix 3
Helix 4
Cyclophilin b.l.
Helix 5
Helix 6
Helix 7
Helix 8
Helix 9
Helix 10
Helix 11
MHR
Interdomain linker
Helices (all)
Loops (all)
NTD
CTD

Number of
viable mutants
7
1
0
1
2
4
0
0
0
2
2
2
1
3
5
11
22
27
13
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Number of
nonviable mutants
3
4
7
3
10
1
2
7
9
5
4
1
5
6
0
57
35
68
27

% viable
mutants
70
20
0
25
17
80
0
0
0
29
33
67
17
33
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16
39
28
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Figure 14. Linear distribution of fitness effects of single residue CA mutations. Plot of
fitness values for CA mutants in which the location of the mutation is arranged on the X-axis from
left (N-terminal residue) to right (C-terminal residue) with their corresponding fitness values (as
the % of WT in the spreading replication assay, as described in Table 1) plotted on the Y-axis.
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Figure 15. Mapping of CA fitness to the CA hexamer structure. (A, B) Location of single
amino acid mutant residues on an X-ray crystal structure of the CA hexamer (PDB: 3GV2).
Images on the left show the hexamer as viewed from the exterior of the intact capsid, while center
images show the hexamer as viewed from within the plane of the capsid lattice, and rightmost
images show the hexamer as viewed from the interior of the intact conical capsid. Green
residues, shown in (A), are those that had greater than 2% of WT fitness in a spreading
replication assay when mutated (viable mutants). Red residues, shown in (B), are those that had
less than 2% of WT fitness in a spreading replication assay when mutated (nonviable mutants).
For residues with more than one mutation, the most fragile result was plotted. (C) Comparison of
fitness and residue surface exposure, as determined by the solvent accessible surface area
(calculated using UCSF Chimera with PDB 3GV2). Mutated residues were grouped as having
2
2
either a solvent accessible surface area <50Å or a solvent accessible surface area >50Å .
Fitness is plotted in accordance with the grouped residue. Significance was determined using
unpaired, parametric t-tests.
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viable mutants (in green, Figure 15A) appear more likely to occur at surface
exposed residues. Conversely, the mutations shown in the interior regions of the
CA structure almost always resulted in nonviable mutants (displayed in red,
Figure 15B). This observation is particularly evident when the CA hexamer is
viewed from a point of view from the interior of the assembled capsid (Figure
15B, rightmost images), and further emphasizes the impression of an inner CA
‘core’ structure, composed of helices that are particularly intolerant to mutation.
Such findings are further confirmed quantitatively by analysis of the
solvent accessible surface area values for individual mutated residues (Figure
15C). Specifically, the mutated residues with solvent accessible surface area
values less than 50 Å2 (a suitable cutoff for surface exposure based on previous
mutagenesis studies [215]) had significantly larger fitness defects (p=0.003).
These more buried mutant viruses (with solvent accessible surface areas less
than 50 Å2) displayed a mean fitness value of only 2.8% of WT (Figure 15C).
However, viruses harboring mutations in more surface exposed residue locations
(with solvent accessible surface areas greater than 50 Å2) displayed a much
larger mean fitness value, at 18% of WT (Figure 15C).

Chapter 3. Biological basis for the genetic fragility of HIV-1 CA
3.1 Analysis of conditionally nonviable (temperature-sensitive) CA mutants
As has been already mentioned, CA performs numerous critical functions
during HIV-1 replication, including its roles mediating the assembly of immature
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virions (in the context of the Gag precursor) and the formation of a mature conical
capsid. In addition, the optimal stability of capsid is thought to be important to the
uncoating step of the HIV-1 cycle in newly infected cells, and CA is also critically
involved in the import of the viral genome into an infected cell’s nucleus. As it
was unclear which, if any, of these functions was responsible for the extreme
genetic fragility of CA, a number of assays were performed to elucidate the
nature of replication defects in both constitutively and conditionally nonviable CA
mutants.
During analysis of the initial viability screens performed on the entire CA
library (Figure 11 A, B), we observed that a small subset of CA mutants were
viable at a permissive temperature of 35°C, but had severely reduced fitness at a
nonpermissive temperature of 39.5°C, whereas most CA mutants were
approximately equally fit or unfit at both temperatures. This subset of
temperature-sensitive (ts) conditionally nonviable mutants included both single
and double residue mutants, and so CA mutants encoding only single amino acid
substitutions in isolation were generated. In total, eleven single amino acid CA
mutants with large ts replication phenotypes were selected for examination.
Since the initial viability screen in which we identified the presence of ts
mutants had measured replicative fitness over multiple rounds of replication, it
did not determine which specific step in the viral life cycle was impaired in the
constitutively or conditionally nonviable mutants. Thus, it seemed prudent to
determine the single cycle infectivity of the ts CA mutants, utilizing virions
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generated at 35°C, 37°C, or 39.5°C in 293T cells, which were then used to infect
MT-4 cells at 35°C, 37°C, or 39.5°C (Figure 16A, B). As Figure 16A
demonstrates, the parental control, pNHGcapNM, has a consistent viral titer
regardless of the temperature of production or infection. It is also apparent that
most of the ts CA mutants had similar, or modestly reduced, infectivity as
compared to the parental virus when virion production and infection were done at
the permissive temperature (35°C) (Figure 16A). Strikingly however, when
restrictive temperatures were applied during virion production, single cycle
replication of all the ts mutants was inhibited at least 50 to 1000-fold (Figure 16A,
B). Conversely, when restrictive temperatures were applied only during infection,
and not production, the single cycle replication of all of the ts mutants was
completely unaffected. These results demonstrate that the defects associated
with conditionally nonviable ts CA mutants occurred exclusively and irreversibly,
during, or immediately after, particle production, and not during earlier steps of
the viral life cycle (such as uncoating or nuclear import).
Subsequent examination of Gag expression and processing by the ts CA
mutants and WT virus showed similar levels of cell-associated Gag precursor
Pr55 and capsid p24 were present regardless of the temperature of production
(Figure 17A). Alternatively, analysis of extracellular virion-associated p24
showed 57% to 88% reductions in p24 levels at the restrictive temperature for the
ts CA mutants only (Figure 17A). Since it was possible that the ts CA mutants
could have affected either CA stability or recognition by the p24 antibody,
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Figure 16. Conditionally viable (ts) CA mutants display defects only when assembled at a
nonpermissive temperature. (A) Measurements of infectious virion titers from 293T cells
transfected with either the parental or ts single residue mutant proviral plasmids, and placed at
either 35°C (filled circles), 37°C (filled squares), or 39.5°C (filled triangles) for production of
virions, as the distinct plot lines indicate. Titers of viruses from resulting supernatants from each
mutant were measured in MT-4 cells at 35, 37, or 39.5°C, as displayed on the x-axis. Dextran
sulfate was added 16h post-infection to restrict replication to a single cycle. (B) As in (A), but here
the temperature of virus production is indicated on the x-axis and inoculations were done in MT-4
cells at 37°C only.
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Figure 17. All conditional (ts) CA mutants display reductions in extracellular particle yield
at the nonpermissive temperature. (A) Western blot analysis, using an anti-CA antibody, of
cell lysates and virions generated in 293T cells transfected with the indicated ts CA mutant or WT
proviral plasmid. For each mutant, two lanes are shown: on the left is the sample from cells
incubated at 35°C following transfection (Lo, permissive), and on the right is the sample from cells
incubated at 39.5°C following transfection (Hi, nonpermissive). The numbers shown below each
lane specify the fluorescence intensities (LI-COR) associated with the CA protein pelleted from
virion-containing supernatant. (B) Western blot analysis, as in (A), but instead utilizing an antiHIV-1-MA antibody (p17) to show expression in cell lysates and virions for the same mutant
panel. The numbers shown below each lane specify the fluorescence intensities (LI-COR)
associated with the MA protein pelleted from virion-containing supernatant.
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analysis of Gag expression, processing, and particle production by the ts mutants
was also done using an anti-p17 matrix (MA) antibody (Figure 17B). Again we
observed uniform levels of p17 in cell lysates regardless of the temperature of
production. However, there were large reductions in p17 extracellular particulate
expression for the ts CA mutants at the nonpermissive temperature, as the 2.425 fold decreases in p17 indicated that particle production was decreased by 5996%.
While the 2.3 to 25-fold reductions in particle production observed for the
ts CA mutants is smaller than the corresponding 50 to 1000-fold reductions in
infectious virion yield, it should be noted that the majority (57 to 96%) of the
reduction in infectivity must be due to an inability for these mutants to efficiently
generate particles. However, these results do also suggest that since the block
in the generation of particles was not absolute, there was also some degree of
generation of poorly infectious particles, such that attenuation of particle
production by ts CA mutants at the nonpermissive temperature varied, rather
than being entirely defective. Ultimately, the inability of the ts CA mutants to
efficiently generate particles at the restrictive temperature is in alignment with the
observation that it is the temperature during particle production, not infection, that
determined the phenotype we observed for all of the ts mutants, and that all of
these mutants result in significant defects that occur during virion
morphogenesis.
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Interestingly, inspection of both anti-CA and anti-MA ts mutant blots
revealed a specific irregularity in Gag processing. As is typical, the parental
virus generated a single ~41 kDa band that was recognized by both anti-CA and
anti-MA antibodies at permissive and restrictive temperatures (presumably the
p41 MA-CA-p2 processing intermediate, Figure 17A, B). The same was also true
for the ts CA mutants at the permissive temperature, however, at the restrictive
temperature, one to two additional protein species appeared at a similar, but not
identical mobility, to p41. Therefore, for all ts CA mutants, attenuated particle
production was accompanied by a disruption in Gag processing, which may be
further linked to the overall defects in particle yield and infectiousness.
Remarkably, for all eleven ts CA mutants, elimination of the activity of the viral
protease also eliminated the temperature-dependent reduction in particle yield
(Figure 18). This permits the conclusion that the capsid mutations that instigate
temperature-sensitive attenuations of particle production do not do so prior to
activation of the viral protease. Combining this observation with the observation
that the temperature of inoculation did not impact infectivity, permits the
conclusion that all eleven conditionally nonviable CA mutants have defects that
are manifested during, and not before or after, virion morphogenesis.
3.2 Analysis of constitutively nonviable CA mutants
Investigation of the eleven conditionally nonviable CA mutants suggested
that the fragility of HIV-1 CA arises from requirements imposed during production
of particles, and not another portion of the viral life cycle. However, it was

71

Figure 18. The conditional (ts) CA mutant reduction in particle yield is protease
dependent. Western blot analysis of the cell lysates and virions generated by 293T cells
transfected with the ts CA mutants (and WT) expressed in a protease-defective proviral plasmid
(Pr-). Numbers below each lane indicate the fluorescence intensities (LI-COR) associated with
the CA protein pelleted from virion-containing supernatant.
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conceivable that the examination of conditionally, rather than constitutively,
nonviable mutants could have biased this conclusion. To remedy this, a larger
set of 81 constitutively nonviable mutants was examined for their ability to
generate extracellular particles by western blot. (Figure 19A).
A striking number (74%) of constitutively nonviable mutants displayed
greater than 5-fold reductions in extracellular particle yields. Still, a minority
(20%) of the lethal mutations did not significantly impact the magnitude of particle
production (less than 2-fold reductions in total particle yield), but instead resulted
in the efficient generation of noninfectious particles (Figure 19A). The other 6%
of the constitutively nonviable mutants had an intermediate phenotype in which
particle reduction was reduced 2 to 5-fold. Occasionally, such as at residues
K30, M39, and I115, a change to one amino acid resulted in efficient generation
of noninfectious particles, while a change to a different amino acid caused a large
reduction in particle yield. However, there again appeared to be no trends in
amino acid property that could definitively determine what might cause mutants
to efficiently generate noninfectious particles as opposed to causing attenuated
particle formation (Figure 13). In alignment with the hexamer mapping
distribution of the inactivating CA mutants, constitutively nonviable mutants that
yielded WT levels of noninfectious particles also mapped to the inner core of the
hexamer (compare Figures 19B and 15B). Furthermore, we also observed that
many of the constitutively nonviable CA mutants displayed evidence of disrupted
Gag processing, as demonstrated by the presence of additional ~40 kDa Gag
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B

Figure 19. Most constitutively nonviable CA mutants display attenuated particle formation.
(A) Western blots showing cell lysates and virions from nonviable mutants (those with <2% of WT
fitness in a spreading replication assay) probed with an anti-CA antibody. It should be noted that
multiple individual substitutions between residues 159 and 168 yielded diminished signal when
the monoclonal anti-CA antibody was used (derived from hybridoma 183-H12-5C). To this end,
CA carrying a R167Q mutation is infectious, but is not recognized by this antibody (unpublished
observation) suggesting that the epitope of the antibody lies in this region. Therefore, it is likely
that the E159V substitution, shown in A, may also disrupt antigen recognition, accounting for the
lack of signal in this lane. (B) Locations of mutations in the CA hexamer that are constitutively
nonviable, but express near WT levels of particle formation. The image on the left shows the
hexamer as viewed from the exterior of the intact conical capsid, the center image shows the
hexamer as viewed from within the plane of capsid lattice, and the rightmost image shows the
hexamer as viewed from the interior of the intact conical capsid.
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protein species, very similar to those present in conditionally nonviable mutants
at the restrictive temperature (Figures 19A, 17A, and 17B). Taken collectively,
these data reinforce the conclusion that the primary determinant of mutational
fragility in HIV-1 CA is the requirement to mediate the efficient and accurate
assembly of particles.
3.3 Evaluations of fragility by electron microscopy
To further investigate the nature of the defects in conditionally and
constitutively nonviable CA mutants, we utilized electron microscopy (EM) to both
quantify and visualize particle morphogenesis. First, to examine the ts CA
mutants, 293T cells were transfected at 39.5°C with either the parental proviral
plasmid or one of six randomly selected ts CA mutant proviral plasmids, plus a
plasmid expressing a modified Vpu-resistant human tetherin (delGI, T45I) [212],
in order to maintain virions at the plasma membrane to facilitate visualization.
Examination of 150 cells for each ts CA mutant revealed that these mutants
generate drastically fewer particles at the restrictive temperature (Figure 20A,
shaded bars), with reductions ranging from 4 to 221-fold (75 to 99.5% fewer
particles). Visualization of the particles revealed that some of the particles
generated by the ts CA mutants seemed morphologically normal, but there also
appeared to be a higher fraction of irregular particles and budding structures as
compared to the parental virus (Figure 20B). Overall, the smaller number of
discernible viral structures produced by the ts CA mutants meant it was difficult to
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Figure 20. Electron microscopic analysis of particle formation by conditionally nonviable
CA mutants. (A) Analysis of thin-section EM images showing the total number of particles
produced by either parental virus or ts CA mutants at the restrictive temperature (39.5°C) in 293T
cells. Circles represent the number of particles produced by individual cells (n=150 cells for each
sample), while the shaded bars indicate the total number of particles counted in the 150 cells. (B)
Representative images of the thin-section EM samples analyzed in (A). Scale bars apply to all
images.
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draw definitive conclusions about the morphological characteristics of the
particles that were produced.
Thin-section EM analyses were also conducted on 293T cells transfected
with three randomly selected constitutively nonviable mutants (K25I, L52F, and
N195S) that had shown significantly reduced extracellular particle yields (Figure
21A, B). As before, this was done in the presence of tetherin (delGI, T45I) to
enable inspection and quantification of viral particles. These analyses revealed
large reductions in particle yields similar to those that characterized the
conditional ts CA mutants. In this case, particle yields were reduced ~6 to 28fold (82 to 96% fewer particles) as compared to the parental virus. For mutants
K25I and L52F, the small number of particles generated appeared to have
morphologies similar to the parental virus, but the budding structures produced
by mutant N195S were obviously abnormal (Figure 21A, B). Intriguingly, irregular
morphologies very similar to those observed for N195S were previously reported
for mutations at a nearby CA residue, D197 [155].
So as to provide an additional control for these experiments, we also
investigated particle production by EM for a constitutively nonviable mutant
(G60W) that displayed high levels of noninfectious particulate p24 in western blot
analyses (Figure 21A, B). This mutant actually produced even more numerous
particles than the parental virus. Together, the data obtained from the EM
analyses of particle formation broadly supported the estimates of particle
formation efficiency obtained from western blot assays (Figure 17A, B, and 19A),

77

A

Constitutive mutants

Number of particles

1200

1137

1000
863
800
600
400
200

151
36

31

N

19

5S

F
L5
2

I
25
K

W
G
60

P

0

37° C

Figure 21. Electron microscopic analysis of particle formation by constitutively nonviable
CA mutants. (A) Analysis of thin-section EM images showing the total number of particles
produced by either parental or constitutively nonviable CA mutants in 293T cells at 37°C. Circles
represent the number of particles produced by individual cells (n=150 cells for each sample),
while the shaded bars indicate the total number of particles counted in the 150 cells. (B)
Representative images of the thin-section EM samples shown in (A) for WT and samples with
reduced particle yields. Scale bars shown apply to all images. (C) Representative thin-section EM
images for three constitutively nonviable CA mutants that had high yields of noninfectious
particles. (D) Cryo-EM images of purified virions from either parental virus or four constitutively
nonviable CA mutants that had high yields of noninfectious particles.
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and further emphasizes the notion that most randomly introduced CA mutations
cause substantial attenuation, but not complete elimination, of particle formation.
Since a minority (20%) of constitutively nonviable mutants resulted in
normal levels of extracellular particles that were noninfectious, we randomly
selected an additional three such mutants (R18G, G60W, and M215V) for thinsection EM examination (Figure 21C). None of these mutants displayed particle
morphologies that notably differed from particles produced by the parental virus.
Moreover, inspection of cell free virions produced by these same mutants, plus
one additional nonviable mutant (K30N) was also done by cryo-electron
microscopy (Figure 21D). Particle morphologies for these mutants again
appeared similar to the WT, perhaps with the exception of G60W, which
displayed cores that were more difficult to discern.

Chapter 4. Analyses of CA library mutations in natural HIV-1 subtype B
populations
4.1 Occurrence of library CA mutations in an in vivo cohort
The in vitro measurements of HIV-1 CA mutant fitness suggested that the
high degree of fragility could place tight constraints on the sequences of CA that
are found in natural populations. Consequently, we obtained a set of 1,000 CA
sequences isolated from HIV-1 subtype B infected individuals, so as to compare
the fitness of our individual library single amino acid HIV-1 CA mutants with the
frequency of their occurrence in vivo. From a plot in which in vitro replicative
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fitness of CA mutations is measured against the frequency with which the
mutations occur in natural populations (Figure 22A), it is clear that only mutants
that exhibited at least 40% of parental virus fitness in our spreading infectivity
assays occurred at a frequency greater than 1% in natural populations.
Curiously, however, there was a distinct bimodal distribution regarding the in vivo
occurrence of the nineteen random mutants that exhibited >40% parental virus
fitness. While some of these fit mutants occurred relatively frequently (i.e. in
>3% of natural sequences, Figure 22B), others occurred extremely rarely or
never (<0.3% of natural sequences, Figure 22C). This indicates that there exists
a subset of mutations that incur little or no obvious fitness cost, but are still
largely absent from HIV-1 subtype B natural populations. Consistent with their
lack of effect on fitness, these seemingly innocuous, but rare, mutant residues
occurred preferentially on the outer surfaces of the hexamer, and avoided the
inner hexamer core (Figure 22D).
4.2 Examination of ‘rare’ and ‘frequent’ mutations in primary cells
The observation that more than half of the random CA mutants that were
fit in vitro occurred either extremely rarely or never in vivo was surprising given
the expectation that HIV-1 will take advantage of all available sequence space
that does not eliminate fitness. Data from these analyses suggested that some
mutations may be selected against in vivo in a manner not initially revealed by
our fitness assays. Earlier studies have determined that certain CA mutations
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Figure 22. Analysis of CA library mutations in natural HIV-1 subtype B populations. (A)
Plot indicating the frequency with which the library mutations occur in 1000 natural HIV-1 subtype
B CA sequences (Y-axis) versus the fitness of the same mutations in a spreading replication
assay (X-axis). The vertical dashed line shows 40% of WT fitness, below which mutants
occurred rarely in nature, while the horizontal dashed line indicates 3% frequency, above which
mutants were considered to occur frequently in vivo. Mutants with less than 0.01% WT fitness
and that were not observed in nature would appear at the origin of the graph, and are not shown.
(B) Library mutants that occurred at a frequency greater than 3% in 1000 subtype B sequences
and their corresponding fitness values. (C) Fit library mutants that occurred rarely (less than
0.3%) or never in 1000 subtype B isolates, and their corresponding fitness values. (D) Mapping of
the residues, shown in (C) on the CA hexamer, where mutations resulted in minimal reductions in
fitness (>40% of WT spreading replication), but occurred in less than 0.3% of subtype B isolates.
The image on the left shows the hexamer as viewed from the exterior of the intact conical capsid,
the center image shows the hexamer from within the plane of the capsid lattice, and the rightmost
image shows the hexamer as viewed from within the interior of the intact conical capsid.
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can have cell-type dependent effects on HIV-1 infectiousness [133,134,216,217],
so it was conceivable that the fit but ‘rare’ mutations might exhibit fitness
defects that are manifested in primary cells, but not in permissive MT-4 cells. To
evaluate this possibility, replication assays were performed in multiple primary
cell types, using 11 apparently fit mutants viruses that occurred rarely in natural
populations (Figure 22C) and 4 randomly selected fit viruses that occurred
frequently (Figure 22B).
Our analyses indicated no significant differences between the ability of
rarely or frequently occurring fit mutations to infect peripheral blood mononuclear
cells (PBMCs), primary CD4+ T cells, or macrophages in short term (semi-single
cycle) infection assays (Figure 23A, B, C). Moreover, there was no significant
difference in the capacity of the rarely and frequently occurring mutations to
replicate in a spreading infection assay in PBMCs (Figure 23C). Ultimately, it
appears that the rarity of certain apparently fit mutations in HIV-1 subtype B
populations is not related to differences in their capacities to replicate in primary
cells. Instead, these findings suggest that there is some unknown selective
pressure that permits some intrinsically fit CA variants, but not others, to persist
in vivo.
4.3 Correlation between fitness and variation in CA
To further examine the relationship between the CA mutations’ fitness in
vitro and their occurrence in natural HIV-1 subtype B populations, analyses were
done to compare naturally occurring variability across the CA sequence (as
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Figure 23. ‘Rare but fit’ CA mutants are indistinguishable from frequently occurring fit
mutants in primary cells. (A) Plot indicating the percentage of infected macrophages after
infection with VSV-G pseudotyped WT virus (NHGcapNM, filled squares) or VSV-G pseudotyped
fit CA mutations (>40% WT fitness) that occurred either rarely (filled circles) or frequently (filled
triangles) in natural sequences. Mutants are those found in Figure 22. (B) Plot indicating the
percentage of infected stimulated CD4+ T cells, as indicated in (A) (not pseudotyped). (C) Plot
showing spreading replication in PBMCs, as indicated by the number of GFP+ cells, after
infection (MOI = 0.1) of stimulated peripheral blood mononuclear cells with virus from either WT
or fit CA mutants that occurred rarely or frequently in isolate sequences.
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measured by Shannon entropy values) with the propensity of CA domains or
regions to tolerate mutation. It seemed a logical expectation that the regions that
are more robust (Figure 14) would have higher levels of variability in natural
populations. Similar to what was shown in a previous analysis of the Shannon
entropy of the N-terminal of subtype C HIV-1 CA [142], our analyses revealed
regions of high entropy in CA (>0.4), and other regions that were more conserved
(Figure 24A). Clearly, there is also a degree of accord between the capacity of
CA domains to tolerate mutation and the Shannon entropy values. This is
particularly evident in regions of comparatively high robustness and high entropy,
such as the cyclophilin binding loop, residues ~5 to ~35, and residues ~175 to
~210. There were also regions in which especially low robustness corresponded
with low variability in vivo, such as helices 2 and 3, and also in the major
homology region (Figure 24A). Nevertheless, there were also some
discrepancies between the Shannon entropy and robustness profiles throughout
CA. For example, fitness measurements revealed helices 5, 6, and 7 to be highly
genetically fragile, but the Shannon entropy values in this region were often quite
high. Ultimately this finding suggests that it is likely that selective pressures in
addition to fitness act on the HIV-1 CA sequence in vivo.
One such selective pressure likely to impose pressure on CA is that of the
adaptive immune system, and in particular, cytotoxic T-lymphocytes (CTLs),
which are able to recognize peptides derived from HIV-1 CA. Several previous
studies have already shown that the selective pressures inflicted by CTLs drive
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Figure 24. Correlation between CA fitness and natural variation. (A) Plot in which the fitness
of the library of CA mutants is overlaid with the Shannon entropy values, derived from 1000
subtype B CA isolate sequences, for each residue in capsid. Locations of CA residues are
arranged on the X-axis from left (N-terminal residue) to right (C-terminal residue), and their
corresponding replicative fitness (as % of WT in a spreading replication assay) and Shannon
entropy values are shown on the Y-axes. The positions of ‘protective’ CTL epitopes are indicated
by horizontal blue lines. (B) Distribution of mutational fitness effects (DMFE), at 37°C, for all
single amino acid CA substitution mutants that occurred either in or outside the protective
epitopes shown in (A).
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certain mutations in CA [142,143,144,145]. More importantly, some of these
studies have demonstrated that immune responses to certain epitopes in CA can
be protective, such that their presence is associated with slower disease
progression. Interestingly, some of the most frequently studied, and most
protective epitopes appear to occur preferentially in regions of extreme genetic
fragility, as can be seen for HLA-B*57-restricted epitopes KF11 (residues 30-40)
and TW10 (residues 108-117), and the HLA-B*27-restricted epitope KK10
(residues 131-140) (Figure 24A, Table 2). Furthermore, a comparison of the
DMFE values for the 41 library mutations that occurred in so-called protective
epitopes (specifically, QW11 (residues 13-23), IW9 (residues 15-23), KF11
(residues 30-40), TL9 (residues 48-56), EW10 (residues 71-80), TW10 (residues
108-117), DA9 (residues 166-174), KK10 (residues 131-140)) with the 94 library
mutations that occurred outside these epitopes indicated that the protective
epitopes occur in regions of CA that are more genetically fragile than the rest of
the CA sequence (Figure 24B). Indeed, whereas the mean fitness value for
mutations occurring outside these protective epitopes was 15.1% of WT, the
mean fitness value for mutations within the epitopes was just 7.9% of WT.
4.4 Summary of effects of random mutations in HIV-1 CA.
By utilizing the scope of the mutagenesis in these studies of CA, in which
almost half of the amino acids in CA were individually mutated, in conjunction
with the analyses of the frequency of these mutations in natural populations, it is
possible to make generalized predictions about the fate of randomly introduced
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nucleotide substitutions (Figure 25A) or amino acid substitutions (Figure 25B) in
CA. For cases of random nucleotide changes (Figure 25A), 22% should result in
synonymous changes that, in most cases, will not affect fitness (Figure 11). If
fitness was the only negative selection pressure in vivo, then 10% of nucleotide
substitutions would be expected to result in a nonsynonymous change that is
sufficiently replication competent (>40% of WT fitness in vitro) to potentially
flourish in natural populations. However the results from Figure 22 suggest that
only a minority of the mutations that yield variants with >40% of WT fitness in
vitro are actually capable of thriving in vivo, and by this limitation, just 4% of all
nucleotide substitutions would be expected to yield nonsynonymous changes that
could flourish in a natural environment.
If only nonsynonymous substitutions are considered (Figure 25B), then
87% should result in nonviable virus, with most mutations (59%) causing >5-fold
reductions in particle formation, and a smaller portion (21%) resulting in the
generation of particles (at at least 20% of the level of WT) that would be
noninfectious. Just 13% of nonsynonymous substitutions are predicted to be
adequately replication competent (at least 40% of WT replicative fitness) to
potentially flourish in vivo, based on intrinsic fitness measurements. Again,
however, only a fraction of intrinsically fit mutants were shown to persist in vivo,
such that only 5% of all CA amino acid substitutions are actually expected to
thrive in a natural environment.
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Figure 25. Summary of the effects of random mutations in HIV-1 CA. (A) Assessment, as
estimated from the in vitro and in vivo data shown previously, of the likelihood of various
outcomes for random single nucleotide substitutions (A) and random single amino acid changes
(B). The charts indicate changes that fall into one of the following categories: synonymous (A
only), nonsynonymous, or nonsense (as determined computationally using the pNHGcapNM CA
sequence). Since the only mutants frequently observed in natural populations are those with
fitness >40% of WT in vitro, this threshold was used to consider which mutants could thrive in
vivo (the proportion of random mutants with fitness less than 40% of WT was derived from data in
Tables 1 and 2). The proportion of mutants expected to thrive (nonsynonymous, viable in vitro
and in vivo) and not to thrive (nonsynonymous, viable in vitro only) was derived from the data in
Figure 22 showing the occurrence of library mutations in natural populations. A red
circumferential line indicates the fraction of random mutants expected to be nonviable in vivo.
Fates of the remaining mutants were derived from the data shown in Figure 19 (nonsynonymous,
noninfectious particles or nonsynonymous attenuated (>5-fold deficit) particle formation).
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Chapter 5. Additional applications of the CA mutant library
5.1 Screen of CA library for resistance to Mx2 restriction
Aside from demonstrating a rather extreme intolerance to mutation, the
randomly mutagenized CA library we have created can also be utilized in other
screening approaches to test the relevance of capsid and its residues in
numerous other HIV-1 functions. Among the biological properties of capsid are
multiple physical interactions with host cell proteins, including karyopherin β
transportin-3 (TNPO3), nucleoporin 153 (NUP153), nucleoporin 358
(NUP358)/RanBP2, cleavage and polyadenylation factor 6 (CPSF6), and
cyclophilin A [128,129,130,131,132,133,218], and it seems likely further proteins
will be added to this list. Work from our laboratory, and others, has recently
highlighted how Myxovirus resistance protein 2 (Mx2, sometimes referred to as
MxB) can efficiently inhibit early steps of HIV-1 infection in vitro [136,137,138].
While the mechanisms by which the interferon-mediated Mx2 suppresses HIV-1
replication have not been clear, these studies have all reported HIV-1 capsid to
be a significant determinant of Mx2 sensitivity, as a few capsid amino acid
substitutions were able to confer either partial or complete resistance to Mx2
activity. These reported mutations reducing sensitivity to Mx2 were largely
localized to the cyclophilin binding loop (at residues 88-90, 92 and 94), but also
included one mutation, N57S, which has previously been reported to impact HIV1 infection of non-dividing cells [127,136,137,138].
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To identify other CA residues that could confer resistance to the antiviral
activities of Mx2, 46 of the CA library mutants that had greater than 2% of WT
infectivity in the single cycle infectivity assay were selected and used to
challenge MT-4 cells expressing Mx2 from various species (Figure 26A). The
ovine and canine variants of Mx2 displayed almost no antiviral activity against
either WT or any of the CA mutant viruses. In contrast, most of the CA mutants
were inhibited by primate Mx2 species variants from human (Hs), macaque
(Mac), and African Green Monkey (Agm) (Figure 26A). Interestingly, however,
seven of the CA mutants conferred significant resistance to at least one of the
primate Mx2s (Figure 26A, B).
Like the previous studies of Mx2, several mutations in the cyclophilin
binding loop were able to confer resistance to Mx2. These included the P90T
substitution, which had not previously been reported, and conferred total
resistance (in Hs), as well as substitutions at newly implicated residues, H87R
and Q95L, that conferred significant partial resistance, to varying degrees, in the
different primates. Identification of these two mutations, together with the
previously established Mx2 resistant capsid mutations, suggests that the
cyclophilin binding loop is likely an important Mx2 sensitivity determinant.
Perhaps more interesting was the identification of the other CA mutants
promoting Mx2 resistance. Two mutants in the N-terminal domain conferred at
least partial resistance, M10I and N57S. While the N57S mutant was previously
reported, the M10I mutant, located in the N-terminal β-strand, was a far more
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Figure 26. Screening of viable CA library mutants for resistance to Mx2. (A) Screen
indicating the level of infection, as compared to non-doxycycline treated controls, for 46 CA
mutants (those viable in single cycle infectivity assays) in doxycycline treated MT-4 T-cells
expressing doxycycline inducible Mx2. Multiple species variants of Mx2 were tested for
resistance, as shown on the X-axis. Mutants are represented by individual circles. (B) The levels
of infection for the 7 CA mutants conferring the greatest resistance to Mx2 identified in (A). Viral
titers were measured in MT-4 T-cells expressing doxycycline inducible Mx2 species variants with
either WT (NHGcapNM) or CA mutants, in the presence of pre-treatment doxycycline, except in
the case of the control (HsMx2-MT-4 with no doxycycline treatment).
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surprising result. Intriguingly, this residue, like the residues in the cyclophilin
binding loop, is a part of the cytosolic surface of mature CA that is known to be
available to inhibitory interactions. Furthermore, M10 and cyclophilin binding
loop residues have been previously reported to be involved in escape from
another antiviral factor, TRIM5α [140,219]. Outside of the N-terminal domain,
there were two previously unreported mutants in the C-terminal domain that also
conferred partial resistance to Mx2, M185I and E187V. Interestingly, residue
M185 is known to be involved in a vital hydrophobic contact at the CA
dimerization interface [220]. As for mutant E187V, it appeared to convey only
partial resistance to Hs and Mac Mx2, but gave nearly complete resistance to
Agm Mx2 (Figure 26B).
When the seven mutant residues conferring resistance to Mx2 in the
screen were mapped onto the capsid hexamer, a certain trend was apparent
(Figure 27). In general, residues conferring resistance were localized to very
exposed surface areas. This is perhaps not entirely surprising given the
propensity for residues in the cyclophilin binding loop to be involved in Mx2
escape, but it was intriguing that the trend also extended to the C-terminal
exposed residues, and the N-terminal M10 residue. The higher surface exposure
of these residues within the mature CA hexamer may mean they are more
accessible for direct interactions with host factors like Mx2. As the CA library is
not inclusive of mutants for all of the exposed surface residues, it is likely that
there are other residues in these locations that could confer resistance to Mx2.
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Figure 27. CA mutant residues conferring Mx2 resistance typically occur in surface
exposed regions of the CA hexamer. The locations in the CA hexamer (PDB: 3GV2) of the
seven residues identified in the CA-Mx2 resistance screen conferring the greatest degree of
resistance are shown in green. The image on the left shows the hexamer as viewed from the
exterior of the intact conical capsid, the center image shows the hexamer from within the plane of
the capsid lattice, and the rightmost image shows the hexamer as viewed from within the interior
of the intact conical capsid.
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In summary, this screen of CA library mutants for Mx2 resistance highlights how
valuable a resource the CA random mutants can be for probing functions and
interactions with a variety of proteins and molecules.

Chapter 6. HIV-1 IN and creation of a randomly mutagenized IN library to
better understand genetic robustness and fragility
6.1 Introduction to genetic robustness in HIV-1 IN
Having evaluated the robustness of HIV-1 CA, determined the biological
basis for its extreme fragility, and investigated correlations between in vitro CA
mutant fitness and in vivo occurrence, we were curious as to how unique CA’s
fragility may be. Satisfying this interest required evaluating the robustness of
another HIV-1 protein in a similar manner. Evaluation of the genetic robustness
of another essential HIV-1 protein could also reveal more significant patterns
about how competing selection pressures, such as those to both maintain
structure and function, and to also diversify sequence to evade immune pressure,
are likely to play out in other HIV-1 proteins.
Like HIV-1 CA, HIV-1 integrase (IN) is a highly conserved, essential, and
multifunctional protein, and it is also the enzyme responsible for the integration of
the viral genome into the host chromosome. It has previously been suggested
that enzymes like IN may be particularly sensitive to mutation given their
requirement to adopt and change their tertiary structure in very subtle and flexible
ways [92]. The relatively highly conserved nature of IN also suggests it could be
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vulnerable to substitutions [156]. Finally, the requirement for IN to interact with a
number host factors, as is similarly true for CA, may also contribute to genetic
fragility.
As the studies of CA robustness demonstrated, a protein’s structure can
influence its genetic robustness. While the X-ray crystal structure of the HIV-1
intasome, the tetrameric dimer of dimer IN-viral DNA functional structure, has not
yet been determined, the publication of the crystal structure of the prototype
foamy virus (PFV) intasome [166,167] has provided further insight into the
possible arrangement of HIV-1 IN’s domains within the tetramer. It has also led
to new and improved HIV-1 intasome models [164], one of which will be utilized
in the subsequently described robustness studies [168].
Understanding the robustness of HIV-1 IN is particularly valuable given the
highly beneficial clinical contributions integrase inhibitors have already made, and
the further therapeutic potential IN holds [221]. In this second study of genetic
robustness in HIV-1, the generation of an even larger unbiased mutagenesis
library will be described, in which the in vitro robustness of HIV-1 IN and CA can
be compared, and further analyzed in conjunction with the in vivo occurrence of
IN mutants. To this end, creation of a large, random IN mutant library will also
permit the utilization of a recent HIV-1 intasome model in which it will be possible
to identify the striking vulnerability of particular IN regions to mutation.
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6.2 Comparison of IN and CA variability in vivo
In order for comparison of the robustness of HIV-1 IN and CA to be
meaningful, it was necessary to establish, as quantifiably as possible, how
similarly the two proteins might maintain mutations in vivo. As robustness
describes a tolerance to mutation, it seemed prudent to compare how frequently
variants, introduced by reverse transcription or RNA polymerase II, actually
appeared in separate cohorts of 1,000 HIV-1 subtype B sequences isolated from
infected individuals for each protein. By measuring the number of sequences
that varied from the parental sequence at each residue in both proteins, it
seemed possible to establish how similarly each protein might tolerate mutations.
When variation amongst the 1,000 HIV-1 subtype B sequences for CA and
IN is mapped in a landscape fashion, CA and IN appear to have relatively similar
mutation frequencies in vivo (Figure 28A, B). The peaks denoting quite high
variability from WT are present at comparable rates—around 9 individual
residues in IN and 11 unique residues in CA contain at least 20% variation (such
that of the 1,000 sequences for each protein, at least 200 sequences varied from
the parental sequence at those distinct residues). IN and CA also share a similar
incidence for the residues indicating little or no variance. The similarities
between IN and CA variation are also particularly apparent when the frequencies
of variants at a residue are arbitrarily binned (Figure 28C, D). The percentage of
residues with a given frequency range of variability differs between IN and CA the
most for residues with high variability (3.1-30% variants at a residue), as 13% of
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Figure 28. Comparison of naturally occurring variation in HIV-1 IN and CA. (A, B) Survey of
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CA residues and 19% of IN residues have this degree of variability. Still, the
percentage of residues with low (0-0.3%), intermediate (0.4-3%), and very high
(>30%) variability is strikingly similar. Ultimately, surveying the naturally
occurring variation in IN and CA suggests that similar proportions of mutations
are tolerated in vivo, implying that comparing IN and CA robustness is not only
fitting, but an endeavor that may reveal similar degrees of fragility.
6.3 Creation of the randomly mutagenized IN library
For construction of the randomly mutagenized IN library, the procedures
were analogous to those used for generation of the CA library (Figure 29A, B).
As before, a low fidelity PCR method, Genemorph II, was used to produce errorprone IN encoding sequences. These mutagenized sequences were digested
and inserted into the replication competent clone, pNHGintBS, using the unique
BstBI and SpeI restriction sites. The pNHGintBS is nearly identical to the
pNHGcapNM (accession: JQ686832) used for the construction of the CA library,
and differs only by the creation of the BstBI site and reconstruction of the SpeI
site to flank IN. Like pNHGcapNM, pNHGintBS encodes EGFP in place of Nef,
and it will hereafter be referred to as the parental or WT virus for experiments
investigating IN, as will pNHGcapNM for experiments involving CA.
6.4 Composition of the IN library, and comparison with the CA library
Subsequently during the IN library construction, around 770 single
colonies were isolated and cultured, and proviral plasmid DNA was extracted and
sequenced. After removal of clones that had either failed sequencing reactions,
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Figure 29. Generation, characterization, and comparison of the IN and CA randomly
mutagenized libraries. (A) Schematic that illustrates the PCR-based mutagenesis of the 864 bp
amplicon containing HIV-1 IN, which is flanked by BstBI and SpeI restriction sites. Subcloning
into the replication-competent proviral plasmid pNHGintBS followed Genemorph II mutagenesis of
the amplicon. (B) Schematic that illustrates the PCR-based mutagenesis of a 717 bp amplicon
containing HIV-1 CA (and a few residues of MA), flanked by NotI and MluI restriction sites.
Subcloning into the replication competent proviral plasmid pNHGintBS followed Genemorph II
mutagenesis of the amplicon. (C, E) Distributions of the number of nucleotide substitutions found
in each clone in the IN (C) and CA (E) mutant libraries (including nonsense and duplicate
mutations, mutations in MA and frameshifts). (D, F) Distributions of the number of amino acid
substitutions found in each clone in the IN (D) and CA (F) mutant libraries (including nonsense
and duplicate mutations, mutations in MA, and frameshifts).
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chromatograms that indicated the presence of more than one template, or that
showed evidence of recombination, 683 clones remained, and the distribution of
their nucleotide changes (Figure 29C) and amino acid substitutions (Figure 29D)
was determined. Comparing these IN library composition analyses with the
distributions of CA library nucleotide changes (Figure 29E) and amino acid
substitutions (Figure 29F) exposes the difference in the error or mutagenesis
rates used during the creation of the two libraries. Whereas the conditions for the
CA library led to a single nucleotide change being the most frequent mutational
outcome, the optimized lower mutagenesis rate utilized for the generation of the
IN library meant far fewer clones had multiple nucleotide changes. Thus, the IN
library yielded more single nucleotide substitution clones from a smaller pool of
clones. Accordingly, this trend is reiterated in the distribution of amino acid
substitutions (Figure 29D, F), and therefore the IN library included more mutants
with single amino acid substitutions than the CA library. It is these mutants that
will be employed in the work described hereafter.
From the resulting single amino acid mutants in each library, additional
clones were removed due to the presence of nonsense mutations, duplicate
mutations of clones already in the library, frameshifts, or mutations outside the
gene (only the case for the CA library, in which a very small fraction of matrix was
in the mutagenized amplicon). As a result, the final IN library contains 156 single
mutants, which cover 118 (41%) of the 288 IN residues, and, as previously

100

described, the CA library contains 135 single mutants covering 102 (44%) of
CA’s 231 residues.

Chapter 7. Evaluations of IN library robustness and comparison with CA
7.1 Fitness of single residue IN mutants
To compare the robustness of HIV-1 IN and CA, the fitness of single
mutants was analyzed in two assays, as described and completed previously for
the CA single amino acid mutants. To briefly reiterate, in the single cycle
infectivity assay, 293T cells were transfected with either WT or single residue IN
mutant proviral plasmids, and the resulting virus-containing supernatant was
added to MT-4 cells (at an MOI of ~1 for the WT virus), which were treated with
dextran sulfate 16h post-infection to restrict infection to a single cycle.
Alternatively, to measure replicative fitness, virus-containing supernatant
harvested from WT or single IN mutant transfected 293T cells was added to MT4 cells in a much smaller dose (at an MOI of ~0.01 for the WT virus), after which
multiple rounds of replication were permitted until the WT virus had infected
>50% of cells (approximately 80 hours later) and the experiment concluded. In
both assays, fitness was calculated using the number of infected (EGFP-positive)
cells, expressed as the percentage of the number of cells infected by the WT
virus. So as to distinguish between robust and fragile mutants in these assays,
the same arbitrary cut-off for viability used for evaluating the CA library was again
employed and generously set at 2% of parental virus fitness, below which it is
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unlikely a virus would be able to thrive in vivo. Since the replicative fitness assay
incorporates a low-dose challenge and multiple replication cycles, this assay is
likely a better determinant of how a mutant virus might behave in vivo, and for
this reason, mutants with less than 2% of WT fitness in this assay were
considered nonviable in evaluations of both the CA and IN libraries.
Considering the indispensable nature of HIV-1 IN, and its resemblance in
variability to CA, it was surprising to discover that just 35% of single IN amino
acid substitutions resulted in nonviable virus by the replicative fitness assay,
whereas twice as many, 70%, of single CA amino acid substitutions were
nonviable in the same assay. The comprehensive list of the 101 viable IN
mutations, with replicative fitness >2% of WT, can be found in Table 4, while the
55 nonviable IN mutants can be found in Table 5. The analogous single cycle
and replicative fitness measurements are available for CA in Tables 1 and 2. As
was also true for CA, comparison of IN Tables 4 and 5 reveals how different
substitutions at the same residue can sometimes result in vastly different fitness
outcomes, as is the case for residue C65, indicating that the type of residue
change can be important. More often, however, multiple unique aa changes at
the same residue resulted in relatively similar fitness. Analysis of the role of an
IN mutant’s type of residue change, with regard to hydrophobicity or molecular
weight, in determining fitness did not reveal consistently significant trends (Figure
30A, C). However, polar basic IN residues were generally more sensitive to
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Table 4. Fitness measurements of viable HIV-1 IN mutants
IN
mutant
E10D
E13V
S17N
P30H
P30S
K42I
K42R
A49V
M50I
M50L
M50V
Q53L
V54A
D55E
D55N
C56Y
G59E
C65S
L68S
V72D
L74M
V75I
V75L
V77I
Y83H
P90L
P90Q
A91T
A91V
T93I
Q95L
L102F
T112I
T112R
V113L
T115I
S119N
S123N
S123T
T124I
T124S
T125A
V126F
K127T
A129S
A129T
A129V
W131C
Q137H
E138D
P145S

Single
cycle
infectivity
a
(% of WT)
91.5
78.4
91.8
9.5
11.3
71.8
77.6
77.4
89.3
100.2
80.6
63.9
87.0
45.4
79.9
108.6
95.2
80.7
94.2
35.9
73.6
99.7
90.1
82.5
77.9
38.2
73.8
73.3
81.6
19.5
42.0
18.2
92.9
66.6
105.0
18.1
5.5
54.6
13.5
74.8
110.1
119.8
86.9
58.8
36.1
43.6
20.3
24.6
97.9
103.7
19.6

Spreading
replication
infectivity
b
(% of WT)
107.9
93.9
141.2
3.9
2.3
71.2
87.7
79.9
75.2
86.2
71.1
39.7
89.9
30.3
65.7
91.1
65.0
60.6
103.6
15.6
64.5
73.4
68.8
56.8
52.5
16.9
66.4
44.6
46.5
15.5
35.3
13.3
61.8
44.1
86.9
7.9
2.2
40.4
3.3
58.1
94.2
92.0
82.9
39.1
28.6
35.0
9.6
15.2
87.4
90.4
3.3

IN
mutant
Q148R
I151T
K156T
K159M
K160E
I162T
G163R
Q164H
D167E
E170K
L172F
T174I
V176I
V180I
F181Y
H183Q
G189E
G197W
E198Q
I200M
I203L
I203M
I204V
A205S
T210I
K211R
Q214E
Q214H
Q214L
K215R
K215T
Q216H
N222I
N222Y
K236I
K244N
I251V
Q252H
S255I
D256V
I257L
I257M
I257V
K258R
P261S
M275L
G277S
A282T
D286N
D288G

Single
cycle
infectivity
a
(% of WT)
33.0
32.4
36.0
44.7
26.5
6.0
117.1
65.1
92.6
64.9
91.0
44.3
9.5
51.6
68.3
11.8
24.6
13.2
89.8
85.5
86.5
101.5
82.6
84.3
45.3
63.0
79.1
79.0
13.5
86.4
54.7
83.6
14.8
85.2
65.1
39.7
74.1
77.4
87.1
98.5
77.0
66.3
79.0
88.4
102.0
65.0
67.3
99.2
101.1
107.8

Spreading
replication
infectivity
b
(% of WT)
13.8
12.0
15.7
29.5
11.8
3.1
105.1
107.2
132.9
88.8
143.4
57.9
6.6
63.6
95.1
9.6
8.6
8.4
91.5
98.5
98.0
101.5
87.0
79.0
44.6
55.7
79.1
54.8
5.2
86.3
25.9
102.1
5.8
93.8
23.0
21.4
92.0
89.6
70.1
53.3
65.3
34.4
48.7
62.6
85.8
47.7
49.8
87.2
122.4
86.4

Viable, or infectious, mutants were those with at least 2% of WT infectivity in the spreading replication assay.
a
Fitness measurement in which MT-4 cells were inoculated, at MOI=1 for the WT virus, with virus-containing
supernatant from 293T cells transfected with single residue IN mutant proviral plasmids. At 16h postinfection, dextran sulfate was added to limit replication to a single cycle. Values shown are the percentage
of infected cells (GFP+) as compared to WT.
b
Measurement of infectivity in which MT-4 cells were inoculated, at MOI=0.01 for the WT virus, with viruscontaining supernatant from 293T cells transfected with single residue IN mutant proviral plasmids. Multiple
replication cycles were allowed over an 80h period. Values shown are the percentage of infected cells
(GFP+) as compared to WT.
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Table 5. Nonviable HIV-1 IN mutants
IN
mutants
G4E
N18I
K34E
V37E
C40F
G52R
D64E
C65F
C65Y
A76S
A76T
V77F

N144I
E152D
N155Y
V165L
R166I
M178V
A179V
I182M
I182N
K188E
K188N
G192E

H78L

A196G

S81N

G197E

I84V

G197R

A86T

E198K

A86V

D202E

E87G

I204K

L102S

E212D

K103E

L213F

W108R

R228W

P109Q

K244I

P109S

V249E

V113A

I251K

G118D

K258E

W132C

K266N

I135F

R269G

I135T

Mutants were considered nonviable if they had less than 2% of WT infectivity in the spreading replication
assay, as described in Table 4.
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Figure 30. Mutational fitness in IN and CA is not definitively determined by changes in
hydrophobicity or molecular weight. (A, B) Evaluation of the effect of mutant residue changes
in hydrophobicity in IN (A) and CA (B) on fitness. Figure legends indicate the abbreviations used
to designate the initial hydrophobicity of a residue and the resulting change. Analyses of
disparities between conservative changes (i.e., polar (P) to polar (P)) and nonconservative
changes (i.e., polar to nonpolar (NP)) were performed for all scenarios, and all significant
differences are indicated. (C, D) Evaluation of the effect of molecular weight change in IN (C) and
CA (D) library mutants on fitness. Analyses between residue substitutions in which there was no
change in molecular weight and those with either increases or decreases in molecular weight
indicated no significant differences. Significance determined using unpaired, parametric t-tests.
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substitution (see residues 34, 42, 78, 103, 166, 188, 228, 244, 258, 266, 269),
perhaps because these residues are more likely to be involved in DNA binding
[222], but were not entirely sensitive, as not all substitutions at polar basic
residues resulted in significant differences in fitness (residues 127, 156, 159,
160, 215, 236). Overall, analyses of the fitness effects of the type of residue
change in both the IN and CA libraries (Figure 30A-D) suggest that there are no
overarching patterns that can determine how a substitution’s change in
hydrophobicity or molecular weight will affect its fitness. Together, the values
provided in Tables 4 and 5 also provide an opportunity to make more general
observations regarding IN domain fragility. As Table 6 indicates, the CTD
domain is notably more tolerant of mutation than the CCD or NTD.
7.2 Distribution of IN fitness and divergence with CA fitness
The fitness measurements of IN differ from those of CA extensively. As
the distributions of mutational fitness effects (DMFE) measurements for IN and
CA demonstrate, not only are there fewer mutants with severe fitness
attenuations in IN, there are also more IN mutants with intermediate, small, or no
fitness reductions, and this reinforces the notion that IN is more robust than CA
(Figure 31A, B). In many ways, IN mutant fitness distributions are similar to the
DMFE measurements reported for other viruses, including RNA viruses, and this
further strengthens the idea that capsid is unique in its extreme fragility
[86,87,93]. In fact, whereas 89% of random CA single mutants caused >2-fold
reductions in fitness, only 62% of IN single mutants had this effect. When the
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Table 6. IN mutant phenotypes by region

Region

Number
of
viable
mutants

Number
of
nonviable
mutants

Fragility
a
(%)

NTD
CCD
CTD
IN total

8
69
24
101

5
42
8
55

38
38
25
35

Mutants
resulting in
reduced
particle yield
b
(%)
0 (0%)
9 (8%)
2 (6%)
11 (7%)

a

Mutants
resulting in
reduced IN
expression in
c
particles (%)
6 (46%)
25 (23%)
3 (9%)
34 (22%)

Mutants
affecting
clathrin particle
incorporation
d
(%)
2 (15%)
11 (10%)
2 (6%)
15 (10%)

Nonviable
mutants only
affected by loss of
infectiousness
e
(%)
0 (0%)
25 (23%)
5 (16%)
30 (19%)

The percentage of mutants considered nonviable (<2% of WT replicative fitness).
Mutants with at least 2-fold reductions in western blot virion IN expression.
c
Mutants with at least 2-fold reductions in western blot particle production, as measured by levels of p24 in virions.
d
Mutants with at least 2-fold reductions in western blot clathrin incorporation into virions.
e
All nonviable mutants with less than 2-fold reductions in both western blot virion IN expression and western blot particle
production.
b
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Figure 31. Distributions of mutational fitness effects in IN and CA. (A, B) Distribution of
mutational fitness effects (DMFE) for the single residue IN (A) and CA (B) substitution mutants at
37°C.
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fitness of each IN and CA mutant is plotted against its linear position in the
protein (for residues with multiple substitutions, the smallest fitness value is
selected), differences in robustness are further highlighted (Figure 32A, B).
These graphical representations expose stark disparities that exist between IN
and CA robustness. Integrase obviously includes significantly more high fitness
mutants, including some with fitness levels above the parental virus. Perhaps
even more intriguingly, the higher levels of IN fitness in the linear landscape map
relatively randomly, whereas CA tends to display small, localized regions of more
relative robustness (corresponding largely to the β-strand, cyclophilin binding
loop, interdomain linker region, and CTD helix 10) dispersed between regions of
fragility.
7.3 Structural analyses of IN fitness on an HIV-1 intasome model
As noted previously, mapping of viable and nonviable capsid mutants to
the mature capsid hexameric structure revealed remarkable patterns in which
viable mutants were preferentially localized to regions with greater solvent
accessible surface area. To determine if analogous patterns might exist for
integrase mutants, IN library viability results needed to be mapped onto an
integrase model structure. Limited by the lack of crystal structure for the HIV-1
intasome, the most recently published HIV-1 intasome model, based largely on
the crystal structure of the PFV intasome, was employed to model the IN mutant
library fitness results [168]. First, it was necessary to establish the location of the
individual IN subunits within the dimer-of-dimer IN tetramer intasome model
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Figure 32. Comparison of linear fitness distributions throughout IN and CA sequences. (A,
B) Plots with replicative fitness, as the % of WT in a spreading infectivity assay, on the Y-axes,
against the position of mutation on the X-axes, organized from left (N-terminal residue) to right (Cterminal residue). For individual residues in which the IN or CA library contained more than one
mutation, the smallest fitness value is plotted, so as to represent any potential fragility that could
be observed in nature. For the IN mutants (A), the plot displays results shown in Tables 4 and 5,
and for CA mutants (B) the plot displays results shown in Tables 1 and 2.
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(Figure 33A). In this structure, unique colors indicate the individual IN subunits,
while grey regions designate DNA, and magnesium and zinc molecules are
hidden from view. Images, from left to right, model theoretical top, side, and
underside profiles. It should be noted that in this model, like the published HIV-1
intasome models before it, the 2 outer subunits (in yellow and green) comprise
only the CCD and a tiny portion of the CTD (including residues 50-230), while the
inner subunits (red and blue) contain full-length IN [164,168].
Upon mapping the nonviable IN mutants onto the HIV-1 intasome model
structure two remarkable trends were apparent—the first was that the nonviable
IN mutants appeared to be predominantly localized to the interfaces between IN
subunits, in particular the dimerization interface between the inner and outer
subunits (Figure 33A, B). The second observation was that the nonviable IN
mutants were generally more buried within the intasome structure (Figure 33A,
B). Mapping of the viable IN mutants onto the intasome model confirmed both of
these observations, as viable mutants seemed to occur predominantly in surface
locations, away from subunit interfaces (Figure 33C). If the viable and nonviable
IN mutants are mapped together on the same intasome structure, these trends
are even more evident (Figure 33D). To quantitatively verify the observation that
viable residues appeared in more surface exposed positions, measurements
were made for the solvent accessible surface area for each IN residue, in each of
the four monomer subunits. As Figure 33E conclusively illustrates, the nonviable
IN residues, have, on average, significantly lower solvent accessible surface area
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Figure 33. Mapping of IN mutant fitness on an HIV-1 intasome model. (A) Images of an
HIV-1 intasome model [168] showing the individual IN subunits comprising the tetramer. Inner
subunits are shown in red and blue, while outer subunits are in yellow and green. Outer subunits
model only the CCD, while the inner subunits include full-length IN. Magnesium and zinc binding
pockets are not visible, but DNA is shown in gray. The image on the left shows the intasome as
viewed from the top, the center image displays a side profile, and the rightmost image displays a
view from underneath. This intasome model will be utilized for all subsequent intasome images.
(B) Locations of the nonviable (<2% of WT replicative fitness) IN mutants mapped on the
intasome model. (C) Locations of the viable (>2% of WT replicative fitness) IN mutants mapped
on the intasome model. (D) Locations of both viable and nonviable IN mutants mapped on the
same intasome model. (E) Analysis of the correlation between residue viability and solvent
2
accessible surface area (in Å ). Mutated residues were either nonviable or viable, and
corresponding solvent accessible surface area values for each IN subunit for every mutated
residue were plotted, so as to represent the varying degree of surface exposure of individual
residues in distinct subunits. Significance was determined using unpaired, parametric t-tests.
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values than the viable IN mutants (p=0.0002). If the outer subunits of the model
were to include full-length IN, it is likely this observation would only be further
enhanced (given that many of the nonviable mutants are in the CCD, and if the
outer subunits were to contain full-length IN, these nonviable mutants would likely
be more buried by NTD and CTD arrangements, further lowering their solvent
accessible surface area values).

Chapter 8. Other functional impacts of IN mutations
8.1 Characterization of IN mutant phenotypes by western blot
Measuring the in vitro fitness of the IN mutants was a good way of
evaluating IN robustness, but there are other functional measures that could
further inform its robustness in vivo. Using western blot analyses, it was possible
to quantify the effects of all 156 IN library single residue mutants on: particle
production, IN expression in particles, and clathrin incorporation into particles
(Figure 34). Integrase mutants affecting all of these properties have already
been reported, and it seemed prudent to investigate the extent of mutants that
might exhibit such effects [186,209,223]. While the reasons for measuring
particle production and IN expression in the IN mutants are more obvious,
evaluation of clathrin incorporation is interesting as clathrin has previously been
shown to help regulate proteolytic processing of HIV-1 virions during particle
assembly, in a manner dependent on Pol, such that certain mutations in
integrase and reverse transcriptase could abolish clathrin incorporation [209].
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Figure 34. Analyses of the robustness of IN mutants by western blot. Western blots of
virions and cell lysates generated in 293T cells transfected with WT and IN mutant plasmids, and
probed with anti-CA, anti-IN, and anti-clathrin heavy chain antibodies, as indicated. Numbers
shown below each band indicate the fluorescence intensities (LI-COR) associated with the WT or
mutant IN protein that was pelleted from virion-containing supernatant. Virion band blots shown
below the anti-clathrin heavy chain (HC) are a secondary clathrin band appearing on the same
blot, shown for correspondence to virion IN expression. Mutant N18I likely lost the epitope for the
anti-IN antibody, so this mutant was not included in Table 6 conclusions. Phenotypes were
considered reduced from WT if expression levels dropped by at least 2-fold.
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Table 6 shows the summaries of the evaluated phenotypes, as observed by
domain.
To begin more in-depth examination of these blots, it should be noted that
cell-associated Gag expression in both the WT and all IN mutants revealed
consistent levels of both capsid p24 and Gag precursor Pr55, ensuring
transfection efficiencies should be equivalent, and giving confidence to the
subsequent analyses. More interesting is the observation that, consistent with
the in vitro infectivity fitness measurements, only a minority of IN mutants
appeared to have deficiencies by western blot. In total, 34 (22%) mutants had at
least 2-fold reductions in IN expression in virions, and just 13 (8%) had a more
stringent 5-fold reduction (mutant N18I was not included in these calculations, as
it seemed to have lost the epitope for the IN antibody). Notably, a larger fraction,
46%, of mutants in the NTD appeared to have substantial reductions in IN
expression in virions than in the CCD (23%), while a far smaller proportion had IN
expression reductions in the CTD (9%) (Table 6). Additionally, mutants with
decreases in IN expression often occurred in clusters in the CCD (residues 7883, 102-109, 129-132), suggesting certain, smaller regions of IN are particularly
vulnerable in this regard. Not surprisingly, the mutants with reductions in virion
IN expression also had decreases in cell-associated IN expression as well.
Similarly, there was a large degree of concurrence between the mutants with
reductions in IN expression in virions, and those with diminished clathrin
incorporation. While not all mutants with IN expression reductions had clathrin
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incorporation reductions in virions, all mutants displaying reductions in clathrin
incorporation also had reductions in IN expression in virions. This was true for
the traditional heavy chain clathrin band denoted HC (Figure 34), while a smaller
clathrin band on the same blot often indicated comparatively lower levels of
clathrin expression (Figure 34, below HC). Still, there were no viable IN mutants
with at least 2-fold reductions in virion clathrin incorporation, so there was no
further investigation of the clathrin incorporation phenotype.
Very few IN library mutants appeared to display reductions in particle
production. Only 11 mutants (7%) had at least 2-fold decreases in virionassociated p24, and none had the more stringent 5-fold reduction in p24.
Interestingly, none of the mutants in the NTD had considerable reductions in
particle production, nor were any affected by loss of infectiousness only,
suggesting, not entirely surprisingly given past research, that this region is
unlikely to contain many class II IN mutants. Inspection of the mutants with
significant (>2-fold) reductions in particle production also revealed that all of
these mutants also had reductions in virion IN expression (Figure 34), but not all
mutants with reductions in IN expression had reductions in particle production.
Also intriguing is the observation that, of the 55 nonviable single amino acid IN
mutants, 24 (44%) had no significant effect (< 2-fold) on either IN expression in
virions or particle production. Instead, these nonviable mutants impacted
infectiousness only.
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8.2 Mapping of IN mutations with functional disruptions on an HIV-1
intasome model
Given how informative the mapping of IN mutant viability on the intasome
model had proved, it seemed worthwhile to investigate whether more structural
trends could be illuminated by mapping the functional IN phenotypes observed by
western blot onto the intasome model. Strikingly, mapping of the nonviable
mutants with at least 2-fold reductions in particle production exposed a rather
narrow and distinct pattern in which most mutants displaying this phenotype
congregated at the dimerization interface between the inner and outer subunits
(Figure 35A). This localization is particularly apparent when compared to the
mapping of the nonviable mutants without IN expression or particle production
reductions, the so-called ‘infectiousness only’ nonviable mutants, which were
scattered throughout the intasome in a relatively buried fashion (Figure 35B).
Equally remarkable was the mapping of the nonviable IN mutants with at least 2fold reductions in virion IN expression, in which an even greater number of
mutants are localized to the same IN subunit interface region (Figure 36A), which
is again especially clear when compared to the mapping of the nonviable
‘infectiousness only’ mutants (Figure 36B). The degree to which these nonviable
mutants that had no reductions in either particle production or IN expression in
virions occurred in buried locations in the intasome model was significant when
compared to nonviable mutants with reduced IN incorporation (p=0.04) (Figure
36C), emphasizing that the ‘infectiousness only’ mutants are even more buried
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A

B

Figure 35. Localization of nonviable IN mutants affecting particle production in the
intasome. (A) Intasome model images showing the locations of the nonviable IN mutants shown
by western blot to have at least a 2-fold reduction in particle production, as measured by levels of
expression of p24 in virions. (B) Intasome model images showing the locations of nonviable IN
mutants for which western blot analyses indicated no significant reduction in either particle
production (as measured by p24 expression in virions) or IN expression in virions. These
nonviable mutants were affected only by a loss of infectiousness.
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Figure 36. Nonviable IN mutants disrupting IN expression in virions are also highly
localized to IN subunit interfaces. (A) Intasome model images showing the locations of the
nonviable IN mutants shown by western blot to have at least a 2-fold reduction in IN expression in
virions. (B) Intasome model images showing the locations of nonviable mutants for which
western blot analyses indicated no significant reduction in either particle production (as measured
by p24 expression in virions) or IN expression in virions. These nonviable mutants were affected
only by a loss of infectiousness. (C) Comparison of the solvent accessible surface area values
2
(in Å ) for nonviable IN mutants that result in either a reduction in IN expression in virions, or no
reductions in either virion IN expression or particle production (those mutant residues mapped in
(B)). All available subunit values were plotted for the relevant residues in each group.
Significance was determined using unpaired, parametric t-tests.
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than other nonviable IN mutants. Together, the mapping on these intasome
structures highlights surprising and novel findings indicating that nonviable IN
mutations causing reductions in particle production and IN expression in virions
are highly localized to certain IN subunit interfaces.

Chapter 9. Analyses of IN library mutations in natural HIV-1 subtype B
populations
9.1 Occurrence of library IN mutations in an in vivo cohort and comparison
with CA
As earlier demonstrated, the fragility of HIV-1 CA places tight constraints
on the sequences of CA that naturally occur. However, the relative robustness of
HIV-1 IN indicates that IN may have more available sequence space to exploit.
By utilizing the same cohorts of 1,000 HIV-1 subtype B IN and CA sequences
used to evaluate the variability in Figure 28, the in vivo occurrence of the library
IN and CA single amino acid mutants could be determined, and contrasted. Plots
of the frequency with which the IN and CA library mutations naturally occurred
against the replicative fitness of the same mutants, revealed a number of
similarities between the behavior of IN and CA mutants in vivo (Figure 37A, B).
Remarkably, in both IN and CA plots, library mutants required the same amount
of replicative fitness, at least 40% of WT, in order to occur at a frequency >1% in
natural populations (Figure 37A, B). Also notable was the observation that for
both IN and CA mutants with replicative fitness >40% of WT, more mutants never
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Figure 37. Occurrence of library IN and CA mutations in natural HIV-1 subtype B
populations. (A, B) Plots indicating the frequencies with which IN (A) and CA (B) library single
residue mutations occur in 1000 HIV-1 subtype B isolate IN and CA sequences (Y-axes) versus
the replicative fitness of the same mutations (X-axes). The horizontal dashed lines designate a
frequency of 3%, above which mutations were considered to be frequently occurring. Vertical
dashed lines indicate 40% of WT replicative fitness, below which mutants typically occurred rarely
in isolate sequences. Mutants that had fitness values below 0.01% of WT, and that did not occur
in 1000 isolate sequences, are not plotted.
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or rarely (frequency <0.3%) appeared in vivo than occurred at a high frequency
(>3%). Table 7 lists the 11 fit IN mutants that occur frequently, and the longer list
of 22 IN mutants that are equally fit, yet never occur in the 1,000 naturally
occurring IN isolate sequences, along with their corresponding fitness values.
Again, these results are surprising given the generally held notion that HIV-1 will
take advantage of all available sequence space that does not incur significant
fitness costs, and indicates that additional selective pressures may be at play for
both IN and CA.
9.2 Mapping of correlations between fitness, in vivo frequency, and
variability on an HIV-1 intasome model
To explore whether the location of the fit (>40% WT replicative fitness) IN
mutant residues correlated with the frequency with which they occur in vivo,
intasome mapping was used to compare the locations of the subsets of ‘fit and
frequent’ (>40% WT replicative fitness in vitro and >3% frequency in vivo) and ‘fit
and never’ (>40% WT replicative fitness in vitro and 0% frequency in vivo)
mutants. Fit and frequently naturally occurring IN mutants appeared to be
primarily localized in quite surface exposed locations throughout the intasome
(Figure 38A). Alternatively, the fit and never naturally occurring mutants were
typically located in more buried positions throughout the intasome (Figure 38B).
These observations were verified quantitatively by plotting the solvent accessible
surface area values for each IN subunit residue for the fit ‘frequent’ and ‘never’
residues, and the results confirm that the fit and never naturally occurring IN
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Table 7. Opposing frequencies of fit IN mutants in vivo
Fit IN mutants
occurring
a
frequently in vivo
E10D
S17N
M50I
A91T
T112I
T125A
D167E
I203M
K211R
Q216H
D286N

Spreading
replication
infectivity
b
(% of WT)
107.9
141.2
75.2
44.6
61.8
92.0
132.9
101.5
55.7
102.1
122.4

Frequency
in subtype
B isolates
c
(%)
8.7
21.7
9.7
9.9
3.8
25.7
3.1
3.5
17.4
3.1
3.3

a

E13V
K42I
A49V
C65S
V75I
V75L
Y83H
P90Q
S123N
V126F
T174I
V180I

Spreading
replication
infectivity
b
(% of WT)
93.9
71.2
79.9
60.6
73.4
68.8
52.5
66.4
40.4
82.9
57.9
63.6

E198Q

91.5

I203L

98.0

Q214H

54.8

N222Y

93.8

Q252H

89.6

S2551

70.1

D256V

53.3

I257L

65.3

Fit IN mutants
never occurring
d
in vivo

P261S

85.8

M275L

47.7

A282T

87.2

Fit mutants occurring frequently are those single residue mutants with fitness >40% of WT that are found in
>3% of 1000 IN subtype B isolate sequences.
b
Spreading replication infectivity is as described in Table 4.
c
Frequency in subtype B isolates is as described in Figure 37.
d
Fit mutants that never occur are mutations that were not found in any of the 1000 subtype B IN sequences.
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Figure 38. Residue surface exposure is a determinant of fit IN mutant frequency in vivo.
(A) Intasome model images showing the locations of the fit (>40% of WT fitness) IN library
mutations that occurred frequently (>3%) in 1000 HIV-1 subtype B IN isolate sequences. (B)
Intasome model images showing the locations of the fit (>40% of WT fitness) IN library mutations
that never occurred in 1000 HIV-1 subtype B IN isolate sequences. (C) Comparison of solvent
2
accessible surface area values (in Å ) for the fit IN library mutants occurring either frequently (as
shown in A) or never (as shown in B). All available IN subunit solvent accessible surface area
values were plotted for the individual ‘frequent’ or ‘never’ occurring fit mutants. Significance was
determined using unpaired, parametric t-tests.
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residues are significantly more buried (p=0.004) (Figure 38C). While the degree
of surface exposure may not completely explain why some fit IN mutants seem to
not occur in vivo, it appears to be a significantly contributing factor. It is not
entirely clear why more buried positions would be less tolerant to mutation in vivo
in the absence of significant fitness effects. It is possible that fit surface residues
are more variable because their exposure makes them more vulnerable to
unknown pressures, possibly of immune origin. However, it may also be true that
relatively small differences in fitness may still impact the frequency of certain
mutations in vivo, as the average replicative fitness of the fit mutants that
occurred frequently in vivo was 94.3% of WT, but the average replicative fitness
of the fit mutants that never occurred in vivo was just 71.7% of WT.
Having established that the degree of surface exposure contributed to the
naturally occurring frequency of IN library mutations, there was good reason to
investigate whether the degree of surface exposure of IN residues might more
generally explain why some residues are more variable than others in vivo.
Again utilizing the cohort of 1,000 naturally occurring IN sequences, as well as
the variability results found in Figure 28, residues for which isolate sequences
varied from the parental sequence in more than 10% of sequences (variability
>10%) were determined and mapped onto the intasome model (Figure 39A).
Whereas these highly variable residues seemed to be preferentially localized to
exposed locations, residues for which there was no variability observed appeared
more buried (Figure 39A, B). Measurements of solvent accessible surface area
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Figure 39. HIV-1 IN natural variability is highly correlated with residue surface exposure.
(A) Intasome model images showing the location of the residues in IN with >10% variability (as
analyzed in 1000 HIV-1 IN subtype B isolate sequences, and indicated in Figure 28). (B)
Intasome model images showing the location of the residues in IN with no variants (as analyzed
in 1000 HIV-1 IN subtype B isolate sequences, and indicated in Figure 28). (C) Comparison of
2
solvent accessible surface area values (in Å ) for the IN residues that were either highly variable
(shown in A) or not variable at all (shown in B). All available IN subunit solvent accessible
surface area values were plotted for the relevant ‘>10% variability’ or ‘no variability’ residues.
Significance was determined using unpaired, parametric t-tests.
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again confirmed the observations, as residues with no variability had significantly
lower values (p<0.0001) (Figure 39C). Ultimately, within this HIV-1 intasome
model, the degree of IN residue surface exposure seems to be a remarkably
good indicator of both how fit a mutant is, and of how likely it is to occur in vivo.
9.3 Summary of effects of IN mutations and comparison with effects of CA
mutations
Having evaluated the robustness of HIV-1 IN both in vitro and in naturally
occurring populations, in a fashion very similar to what was done for HIV-1 CA, it
was possible to compare generalized predictions of the fate of randomly
introduced nucleotide and amino acid substitutions into the two proteins, to better
emphasize the stark differences in robustness. For random nucleotide
substitutions, an estimated 18% of IN substitutions and 22% of CA substitutions
should result in synonymous changes, which should not, in most cases,
significantly impact fitness. The difference in the proportion of nucleotide
substitutions yielding synonymous changes in IN and CA highlights how the
composition of a protein can impact the outcome of any substitutions. In the
absence of any negative selection pressure other than fitness, then 43% of IN
nucleotide substitutions, and a far smaller 10% of CA nucleotide substitutions,
would be expected to result in nonsynonymous changes sufficiently replication
competent (>40% of in vitro WT fitness) to, at least theoretically, thrive in vivo.
Yet data from evaluations of the natural occurrence of the fit mutations with >40%
of WT fitness (Figure 37) revealed that only a minority of these mutations actually
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persist in vivo in both data sets, such that 12% of IN nucleotide substitutions, but
only 4% of CA nucleotide substitutions would actually be expected to flourish in
natural populations (Figure 40).
When only the nonsynonymous nucleotide substitutions are evaluated,
then 40% of IN substitutions and 87% of CA substitutions would be expected to
be nonviable, with only a few mutations in IN (5%), but most in CA (59%),
inducing significant reductions in particle production (Figure 40). This reinforces
the idea that the basis for the genetic fragility of CA is the need to efficiently and
correctly assemble particles, and that this requirement may be largely unique to
CA. While 60% of IN amino acid substitutions are sufficiently replication
competent (at least 40% of WT fitness) to potentially thrive in vivo, the same is
true for just 13% of CA amino acid substitutions, based on in vitro fitness
measurements. However, these numbers are significantly reduced by the finding
that only a fraction of the intrinsically fit mutants actually persist in vivo (Figure
37), such that 15% of IN amino acid substitutions and only 5% of CA amino acid
substitutions could be expected to thrive in a natural environment (Figure 40).
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Figure 40. Diverse fates for random mutations in HIV-1 IN and CA. Comparison of various
likely outcomes for random nucleotide or amino acid substitutions in IN and CA, as indicated.
Charts show changes that are synonymous (nucleotide substitutions only), nonsynonymous, and
nonsense (as determined by using the pNHGintBS or pNHGcapNM sequences). Substitutions
that resulted in a stop codon were assumed to be nonviable while synonymous changes were
assumed to be viable. Given the observation that only mutants with >40% of WT in vitro fitness
are observed in nature, this threshold was used as a sufficient determinant of mutants that would
thrive in vitro (proportions of mutants with <40% WT fitness were determined using the viable and
nonviable IN and CA mutants in Tables 1, 2, 4, and 5 and are denoted by red circumferential
lines). Ratios of fit mutants expected to thrive in vivo (nonsynonymous, viable in vitro and in
vivo), or expected not to thrive (nonsynonymous viable in vitro only) were derived from data in
Figures 22 and 37. Fates of remaining mutants were determined using western blot data from
Figures 19 and 34 (nonsynonymous, noninfectious particles or nonsynonymous attenuated
particle formation (at least 5-fold deficit for CA and at least 2-fold deficit for IN)).
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IV. Discussion
As the circumstances contributing to the fragility of CA and the relative
robustness of IN are likely to differ significantly, the situation of CA will first be
addressed independently, followed by analyses of the comparative robustness of
IN. Thereafter, the implications about the genetic robustness and fragility of HIV1 proteins will be briefly discussed and given perspective.
The extreme genetic fragility of HIV-1 CA
This study has sought to create a library of random CA mutations
representative of those that occur naturally during HIV-1 infection, and to
examine their biological effects. In so doing, it has been possible to determine
the genetic robustness of HIV-1 CA, and to correlate the effects of amino acid
substitutions in vitro with their occurrence in natural viral populations.
Furthermore, the creation of an extensive CA library constitutes an important
resource for investigating various functions and properties of HIV-1 CA, including
CA’s emerging impact on Mx2 retroviral restriction. Importantly, the results have
demonstrated the extreme genetic fragility of the HIV-1 CA protein, in which the
majority (70%) of unbiased, single amino acid substitutions result in nonviable
viruses (<2% of WT fitness).
In fact, after surveying the literature for all studies that have conducted
mutagenesis in such a way that mutational robustness could be determined, HIV1 CA appears to be the most fragile protein ever described. As Table 8 indicates,
capsid is significantly more fragile than other HIV proteins, as in the next most
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Table 8. Comparison of the robustness/fragility of HIV sequences*
Protein/Domain
HIV-1 capsid

Fragility
70%

#

Author
Rihn et al.

Summary/Notes
This study.
80 out of 131 mutants had negative
activity, as shown by lack of Western
blot p66/p51 bands.
A total 86% of 107 single mutants
were deleterious to catalytic
efficiency, 54% lethal.
Out of 330 single missense mutants,
around 40% were considered
sensitive to mutation.
This study.
From 154 single mutants, 43 had RT
levels that were ≤ 2% of WT.

HIV-1 protease flap
region (aa 46-56)

61%

Shao et al. [224]

HIV-1 protease

54%

Parera et al. [91]

HIV-1 protease

40%

Loeb et al. [225]

HIV-1 integrase
HIV-1 reverse
transcriptase palm
subdomain (aa 164203)
HIV-2 integrase

35%
28%

Rihn et al.
Chao et al. [226]

13%

HIV-1 reverse
transcriptase motif
B
HIV-1
transcriptional
promoter (LTR)
HIV-1 reverse
transcriptase (aa
67-78 of beta3beta4 loop)

12%

van den Ent et
al. [227]
Smith et al. [228]

5 out of 38 mutants display severely
attenuated integration.
Using infectivity results, 3 out of 25
mutants had ≤2% of WT levels.

0%

van Opijnen et
al. [90]

0%

Kim et al. [229]

None of the 15 single mutants
diminished infectivity as much as 2
fold in any cell line.
Fragility measured by genetic
selection in E. coli, in which no WT
aa were essential.

*Table

describes single residue mutagenesis studies that were (i) random (i.e. the cohort of
mutants was not selected, and did not have amino acid bias) (ii) analyzed proteins or domains
#
greater than 10 aa in length, and (iii) had datasets that included at least 5 mutants. Fragility,
when not stated clearly in the published work, was deduced using the % of mutants either
indicated as ‘lethal’ or that had 2% or less fitness or function compared to WT, using the available
analyses of fitness or function utilized in the study. In most cases, wording of summary/notes
mimics the author’s assessment as closely as possible.
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fragile protein, HIV-1 protease, only 40-54% of mutations resulted in nonviability
[91,225]. HIV-1 CA is also more fragile than the small domains of HIV
mutagenized because of their suspected severe fragility, such as the HIV-1
protease flap region or the HIV-1 reverse transcriptase palm domain [224,226].
Likewise, Table 9 demonstrates that HIV-1 CA is also more fragile than proteins
or domains in viruses other than HIV, with human papilloma virus 16 protein E1,
in which 63% of mutations were lethal, coming the closest to the fragility of
capsid (although the study’s extremely small mutant sample size may
overestimate its fragility) [230]. It is perhaps not surprising then, that CA is also
more fragile than the whole viral genomes in which robustness has been
evaluated (Table 10), in which 20-41% of mutations were lethal [87,93]. Viruses
(particularly ss(+) RNA viruses) not only have very high mutation rates, but also
have comparatively low tolerance to mutation [79,83], so it is again perhaps not
unexpected that CA is more fragile even outside the viral context, as the most
fragile nonviral protein described is the essential E. coli lac repressor, in which
41% of residues were estimated to be intolerant of substitution [231] (Table 11,
which is not inclusive of all nonviral random mutagenesis studies, but none were
found that were more fragile).
While the biological basis of the extreme mutational fragility of the HIV-1
CA appears to be the need to coordinate accurate and efficient assembly of
particles (Figure 16-21), it is not immediately apparent why so many CA
mutations result in reduced particle yields. However, it seems likely that CA’s
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Table 9. Comparison of the robustness/fragility of other viral sequences*
Protein/Domain
Human Papilloma Virus
16 E1
Simian
immunodeficiency virus
mac239 envelope
constant region 4
H3N2 influenza A
hemaglutinin

#

Author
Yasugi et al.
[230]
Morrison et al.
[232]

Summary/Notes
5/8 single mutants were unable to
replicate.
Only 11/26 single mutants were
able to replicate appreciably.

56%

Nakajima et al.
[233]

H2N2 influenza A
neuraminidase

53%

Yano et al. [234]

Bacteriophage λ Cro

53%

Pakula et al.
[235]

Mason-Pfizer monkey
virus matrix
Moloney murine
leukemia virus capsid
central domain
Bacteriophage f1 gene
V protein

50%

Rhee et al. [236]

40%

Alin et al. [237]

35%

Varicella-Zoster virus
thymidine kinase

35%

Terwilliger et al.
[238] Masso et
al. [239]
Suzutani et al.
[240]

44% of 248 single aa changes did
not abrogate hemadsorption
activity.
47% of 152 single mutations in NA
were tolerated, certain regions
were more sensitive.
Approximately 37 out of 70 single
residue mutants have ≤2% of WT
CRM levels.
4/8 single mutants had significant
cell-free infectivity.
Virus replication was considered
blocked based on RT levels for 6
of 15 single mutants.
139 out of 371 single point
mutants were inactive (unable to
inhibit E. coli growth).
Out of 17 single aa mutants, 6
resulted in a loss of enzyme
activity.
5 /115 single mutants had ≤2%
WT mini replicon activity, 30/57
tested mutants had titers ≤2% of
WT.
6 out of 25 nonsynonymous
substitutions abolished systemic
infectivity.
From 2015 single aa substitutions,
328 were deleterious enough to
prevent plaque formation.
2/13 single mutants have RT
levels at ≤2% of WT, all other
mutants maintain at least 50%.
Only 1 out of 11 random single
mutants led to a greater than 10
fold reduction in infectivity.
Zero out of 13 single random
mutants had significantly impaired
in vitro translation.

Bunyavirus
nucleocapsid (N)

Fragility
63%
58%

4-26%

Eifan et al. [241]

Wheat streak mosaic
virus HC-Pro

24%

Stenger et al.
[242]

Bacteriophage T4
lysozyme

16%

Rennell et al.
[243]

Mason-Pfizer monkey
virus capsid MHR

15%

Adenovirus VI

9%

Strambio-deCastillia et al.
[244]
Moyer et al. [245]

Encephalomyocarditis
0%
virus internal ribosome
entry site
#
*, Criteria are the same as in Table 8.

Van Der Velden
et al. [246]
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Table 10. Comparison of the robustness/fragility of viral genomes*
Virus
Tobacco etch
potyvirus (whole
genome)
Vesicular stomatitis
virus (whole
genome)
Bacteriophage Qβ

Fragility
41%

#

Author
Carrasco et al. [93]

40%

Sanjuán et al. [86]

29%

Domingo-Calap et
al. [87]

Bacteriophage f1
(whole genome)

24%

Peris et al. [247]

Bacteriophage
ΦX174

20%

Domingo-Calap et
al. [87]

#

*, Criteria are the same as in Table 8.
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Summary/Notes
Out of 66 single mutants, 41%
were lethal and an additional 36%
were deleterious
Fitness analysis of 91 single
mutants showed a further 29% of
mutants were deleterious
29% of single mutations in 42
clones of Qβ were considered
lethal
24% of a total 51 single missense
mutants were lethal. Gene
lethality varied 7 to 47%
20% of single mutations in 45
clones of ΦX174 were considered
lethal

Table 11. Robustness/fragility measurements in nonviral proteins*
#

ORF/Protein/Region
E. coli lac repressor

Fragility
<41%

Author
Markiewicz et al.
[231]

3-methyladenine
DNA glycosylase
(AAG)
Campylobacter jejuni
oligosaccaryltransfer
ase PglB
Human interleukin-3

34%

Guo et al. [248]

33%

Ihssen et al. [249]

29%

Olins et al. [250]

Bacillus
stearothermophilus
α-amylase
TEM-1 betalactamase

20%

Holm et al. [215]

16%

Huang et al. [251]

T15 antibody heavy
chain CDR2
Barnase, a bacterial
ribonuclease

7%

Chen et al. [252]

5%

Axe et al. [253]

Human interleukin-1α

2%

Kawashima et al.
[254]

#

*, Criteria are the same as in Table 8.
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Summary/Notes
From 4000 single mutants, authors
conclude 192 of 328 aa should be
tolerant to substitution
The calculated probability of a
single random amino acid change
inactivating AAG is 34%
16 of the 24 single mutants
maintain strong PglB expression by
ELISA
From analysis of 770 mutants, 71%
of residues were considered
tolerant, as they had ≥5% of WT
bioactivity
12 out of 61 single random mutants
had zero enzyme activity
Authors conclude that 43 of the 263
residues cannot tolerate
substitutions
Just 1 out of 15 single CDR2
mutants lost binding function
5% (of over 600 mutants) were
found to render barnase wholly
inactive
Only 1 out of 56 single mutants
appeared to have significantly
impaired activity

fragility is related to the requirements that it maintain a structure that enables
several different sets of interactions. Within the mature hexameric CA lattice,
each CA monomer must interact, via distinct interfaces, with at least three other
CA monomers, and adopt a quite tightly constrained position with respect to its
internal structure as well as other CA monomers within a hexamer [123]. At the
same time, some CA monomers, that have precisely the same amino acid
sequence, must be capable of assuming slightly different structures and positions
relative to other CA monomers, in order to form the pentameric declinations that
permit closure of the CA lattice [111,117]. Furthermore, another set of CA:CA
interactions are likely required during the formation of immature virions [110].
Beyond these constraints, the strength of the various CA:CA interactions in each
of the different configurations probably needs to finely tuned to allow proper
transitions from immature to mature virions during assembly, and appropriately
timed disassembly of the capsid. Indeed, earlier findings have suggested that
proper capsid stability is required for HIV-1 infectiousness [255]. Additionally, CA
interacts with numerous host proteins, including cyclophilin A [120], ABCE1 [119],
and probably with CPSF6 [132] and nuclear pore complex proteins [131].
Together, the number of CA interactions and functions, and the requirement for
CA to adopt multiple different structures, and transition between them in an
organized manner at multiple, critical stages of replication, likely places tight
constraints on sequence and decreases the number of possible mutations that
will not result in major fitness costs.
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While the lethal CA mutations could, in principle, affect any one of multiple
steps in the HIV-1 life cycle, it appeared that most constitutively nonviable
mutants exhibited attenuated particle formation. Moreover, all of the conditionally
nonviable ts mutants displayed attenuated particle formation at the
nonpermissive temperature. Interestingly, these deficits, at least for the
conditionally nonviable mutants, could be rescued by inactivation of the viral
protease. Ultimately, these results indicate that the critical role of CA in
coordinating efficient and accurate particle assembly, particularly during Gag
proteolysis, is the principal cause of its genetic fragility.
The processes of particle formation, budding and maturation are not yet
fully understood, but over a relatively short period of time (5-6 minutes) [256],
thousands of Gag and Gag-Pol molecules coalesce, in a manner requiring
cleavage and rearrangement through regimented and ordered processes.
Previous work has shown that incorrect, premature activation of the HIV-1
protease can prevent particle formation [257]. Moreover, other perturbations of
Gag (such as a partial nucleocapsid deletion) can attenuate particle formation in
a way that is rescued by inactivation or inhibition of the viral protease [258,259].
One idea that may explain these findings is that delayed particle formation may
result in more extensive, or mistimed, proteolytic cleavage of Gag early in the
assembly process, thereby attenuating particle formation [258,259]. Our finding
that many of the constitutively nonviable and all of the conditionally nonviable CA
mutants showed evidence of disrupted Gag processing, through the presence of
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additional ~40 kDa protein species, is in accordance with the idea that CA
mutations could similarly delay particle formation, resulting in mistimed Gag
proteolysis relative to budding, and, thereby, protease dependent reductions in
particle yields. Within this framework, it is easier to understand how even subtle
perturbations of Gag structure or multimerization, such as those caused by single
amino acid substitutions, could disrupt the delicate process of HIV-1 assembly,
and thus how critical a role CA plays in orchestrating virion morphogenesis.
Earlier work has shown that the N-terminal domain of HIV-1 CA is
dispensable for particle formation [260], which is intuitively at odds with our
finding that many mutations in the N-terminal domain result in diminished particle
production. However, it has already been hypothesized that misfolding of the Nterminus (caused by small changes in CA) may be more disruptive to assembly
processes than deletion [260]. Even without overt misfolding, inclusion of a CA
NTD that does not fit correctly or efficiently into the hexameric lattice is likely to
be more disruptive than NTD absence to the other interactions that are essential
for particle formation (such as the CTD-CTD interactions).
Previous large-scale mutagenesis studies of retroviral CA proteins have
utilized insertional mutagenesis of murine leukemia virus (MLV) CA (using 12
amino acid peptide sequences) [261,262] and alanine substitution of surface
exposed residues in HIV-1 CA [155]. The fact that the 12 amino acid insertions
into MLV CA were uniformly lethal is consistent with the notion that retroviral CA
proteins are generally intolerant of mutation, but insertions are obviously more
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likely to disrupt CA structure than single amino acid substitutions. In fact, a study
of MLV CA mutants revealed that only 6 of 15 single amino acid substitutions
(40%) in the central portion of CA were lethal [237]. Interestingly, this study
found that the most frequent phenotype associated with single amino acid
substitutions in MLV CA was the generation of noninfectious particles, instead of
reduced particle formation, which suggests there may be a difference in the
properties of MLV and HIV-1 CA proteins. Prior to our study of HIV-1 CA, the
most extensive mutagenesis study of HIV-1 CA [155] described 48 alaninescanning mutants that targeted surface exposed residues, of which 44% were
nonviable. This study also found that single mutations in both the NTD and CTD
could cause attenuated or aberrant particle formation, as well as the generation
of virions that appear morphologically normal, but were noninfectious [155]. The
difference between the fraction of mutations that were lethal in [155] versus our
study is in accordance with our finding that viable CA mutants tended to be
confined to surface-exposed residues while mutations of the inner core of the CA
structure were rarely associated with viability.
Most notably in relationship to the CA structure, we found that sequences
encoding CA helices, particularly those in the NTD, were especially genetically
fragile. These sequences form the basic structure of the CA hexamer, and in
some cases (helices 1, 2, and 3), are involved in the CA:CA interactions within
the CA hexamers [123]. Mutations in the CTD helices, and in the interhelical
loops (such as the cyclophilin A binding loop) were less likely to cause lethal
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defects. This comparative tolerance of mutations in certain portions of CA seems
to correlate, at least partially, with conformational variation in crystal structures of
CA hexamers [123]. In short, the CA NTD helices appear to be highly structurally
constrained and particularly sensitive to mutations that might disrupt the shape or
stability of the CA NTD monomer or the CA hexamer.
By correlating our CA library fitness measurements with analyses of the
frequency with which the mutations occur in natural populations, we hoped to
make observations that neither approach alone could reveal, and also make
predictions about the outcomes of hypothetical mutations. For example, all of the
mutations that were present in our library at a frequency greater than 3% in
natural populations (n=9) were relatively fit in vitro (>40% of WT fitness).
Conversely, all the mutants with fitness <20% of WT (n=106) occurred at a
frequency of <1% in natural populations. Together, these findings indicate that
there is indeed some correlation between fitness and occurrence in natural
populations, and suggests that below ~40% fitness threshold, mutations are
unlikely to confer a selective advantage in a human host. Nevertheless, the
correlation between mutant fitness and natural occurrence was not perfect,
indicating that there are likely selective pressures other than fitness in vivo.
Specifically, there was not complete concordance between fitness and Shannon
entropy profiles in some portions of the CA sequence, and it was striking that less
than half of the mutations that had little or no impact on fitness actually occurred
in natural populations (‘fit but rare’ mutants). These findings could be interpreted
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as arising due to either the absence of a selective pressure driving the
emergence of ‘fit but rare’ mutants, or alternatively, because of the presence of
an unknown selective pressure against their emergence. Importantly, in our
examinations of the fit but rare mutants, we were unable to detect any defect in
the ability of these mutants to infect primary cells, including primary T-cells and
macrophages. One possible explanation for these findings is that fit but rare
mutants are eliminated from natural populations because they confer sensitivity
to adaptive or innate immune responses. Taken together, our findings suggest
that only ~5% of all possible amino acid substitutions in CA result in viruses that
can flourish in vivo.
One candidate for selective pressure that induces sequence variation in
regions of high genetic fragility, and could possibly suppress ‘fit but rare’ mutants,
is that imposed by cytotoxic T lymphocytes (CTLs). Already a number of
examples of CTL escape mutations in protective epitopes have been described,
and these have been characterized by their predictability (reoccurrence of the
same mutation in distinct infected individuals) [263], their impact on viral fitness
(sometimes) [144,264], and by their co-occurrence with additional compensating
mutations, suggesting an influence of epistatic interactions that might aid any
compromised fitness induced by primary escape mutations [142,143]. These
findings are in accordance with the finding that CA is extremely genetically
fragile, and suggest that only a small number of possible mutations can permit
escape from CTL responses and still maintain fitness. At the same time, it is
important to recognize that even though our library of CA mutants should be
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representative of random variants, it is still only a sample of the possible
mutations that can arise in CA in natural populations. Previous analyses in cell
culture indicate that a single cycle of HIV-1 replication (incorporating both
transcription and reverse transcription) results in 1.4-3.4 x 10-5 mutations per
nucleotide [79,80]. Within the 231 aa CA protein, this would yield approximately
0.0097-0.023 errors per replication cycle, which is equivalent to an amino acid
substitution once or twice per one hundred replication events. Considering the
large population size and high replication rate of HIV-1 in vivo [265], this means
that every amino acid substitution that can occur by a single nucleotide
substitution is generated in nearly every infected individual, many times each
day. Therefore selective pressures that are imposed in vivo can act on an
enormous pool of possible variants. The discrepancies between the fitness and
Shannon entropy profiles (Figure 24A) suggest that even in regions of CA in
which we found few or no fit mutants amongst 135 library mutants, there are still
rare variants that can thrive in vivo, even if they may exhibit reduced fitness or
require the co-occurrence of compensating mutations.
Previous work has shown that CTL responses to Gag, rather than other
HIV-1 proteins, correlate best with reductions in viral loads, and thereby, often
disease progression, during HIV-1 infection [148]. Interestingly, we observed
that the so-called ‘protective’ CTL epitopes [143] were more likely to occur in
regions of CA that were even more fragile than CA as a whole. As Gag is among
the most abundant viral proteins expressed in HIV-1 infected cells, this
abundance, and the relative lack of plasticity in CA, likely contribute to the fact
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that patients that display strong immune responses to Gag have comparatively
favorable clinical outcomes. Still, the capacity of viral populations to explore all
available sequence space partly overcomes the genetic fragility of CA, and
enables at least some amount of escape from immune responses, even those
that target the most vulnerable regions of CA.
Aside from revealing significant insight into the genetic fragility of CA and
its biological basis, the CA mutant library is also a useful tool for probing other
HIV-1 functions and interactions with cellular factors. Other members of the
Bieniasz lab have previously utilized the single amino acid CA mutants to probe
for mutants affecting: infection of non-dividing cells, resistance to TRIM5α, and
interaction with cyclophilin A. However, it has also been possible to now utilize
the CA library to probe the emerging association between CA mutants and Mx2
sensitivity. While previous work had reported CA mutants conferring resistance
to Mx2 restriction of HIV-1, these mutants were limited to only a few residues in
the cyclophilin binding loop and one other residue (N57, already reported to
impact infection of non-dividing cells) [136,137,138]. Surprisingly, we were able
to identify CA mutations in multiple new regions of the CA protein that were able
to confer resistance to Mx2, some of which had species-dependent effects.
Interestingly, comparison of the mutant residues conferring resistance to Mx2
and TRIM5α reveals significant similarities, often involving the same residues or
precise mutations (such as M10I and P90T) [140,266]. Considering how many
CA mutants have already been shown to impact a number of diverse HIV-1
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functions and interactions with host factors, it seems likely that the CA mutant
library will continue to prove a useful tool with which HIV-1 can be probed.
Recognizing and understanding the fitness effects of mutations in CA may
facilitate drug or vaccine design. For example, a recent study done in the context
of a possible vaccination strategy revealed that mutations in the most conserved
residues in CA are not necessarily associated with the highest fitness costs
[267], as might otherwise be assumed. Thus, an even better grasp of the
constraints under which CA evolves may prove beneficial. Furthermore, while
CA has not yet been exploited as a target for drugs in the clinic, recent studies
have indicated that it is, at least in principle, possible to do so
[268,269,270,271,272]. Capsid’s genetic fragility should reduce, but not
eliminate, the opportunities for drug resistance to occur, and it would thus be
ideal if novel therapeutic treatments were to target the CA domains with the
greatest fragility. In spite of this, resistance to one recently identified CA-targeted
inhibitor has already arisen in vitro through mutations in regions of CA that exhibit
high fragility. This is a testament to how the sheer number of variants that can
be ‘tested’ or explored in natural viral populations, can, at least sometimes,
overcome the lack of robustness in HIV-1 CA. Nevertheless, the high genetic
fragility exhibited by CA should make it a target of novel vaccination or therapy
strategies.
Uneven mutational robustness of HIV-1 integrase
In our second examination of genetic robustness in the context of HIV-1,
we sought to examine the robustness of HIV-1 integrase, in a manner similar
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enough to what was done with HIV-1 CA so as to permit comparison, and to also
survey how the biological effects of IN mutations could be reflected in an HIV-1
intasome model. Using a large randomly mutagenized library of HIV-1 IN single
amino acid mutants, we were able to determine the impact of single residue
substitutions in vitro, observe their functional impact by western blot, correlate
their fitness with their occurrence in natural viral populations, and, perhaps most
importantly, meaningfully map all of these phenotypes onto an HIV-1 intasome
model. The results reveal a surprising, but significant juxtaposition between the
robustness of IN and CA, with just 35% of individual amino acid substitutions in
IN resulting in nonviable (<2% of WT fitness) viruses, whereas twice as many
mutants in CA (70%) had the same effect. This relative robustness is surprising
given the expectation that essential enzymes will be fragile, but is notably similar
to results published from a variety of other mutagenesis studies, many of which
include other enzymes. For example, comparisons of IN’s robustness with other
mutagenized HIV-1 proteins (Table 8), reveals how similar the robustness of IN is
to protease, in which 40% of single residue mutations were inactivating [225].
Furthermore, other viral proteins have been shown to be equivalently robust to IN
(Table 9), such as bacteriophage f1 gene V and Varicella-Zoster virus thymidine
kinase, in which 35% of mutations were inactivating [238,239,240]. In fact, the
robustness of IN is also similar to several whole viral genomes (Table 10),
including Tobacco etch potyvirus, vesicular stomatitis virus, and bacteriophage
Qβ, in which 41%, 40%, and 29% of mutations were lethal respectively
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[86,87,93]. Finally, the robustness of IN is comparable to nonviral enzymatic
proteins (Table 11), such as 3-methyladenine DNA glycosylase (AAG), in which
34% of single amino acid changes were calculated to be inactivating [248], and
campylobacter jejuni oligosaccaryltransferase PglB, in which 33% of mutations
appeared lethal [249]. While IN is more fragile than other HIV proteins and
regions, such as the HIV-1 LTR, in which no mutations (0%) were significantly
deleterious [90], or HIV-2 integrase, where just 13% of mutations could be
considered lethal [227], HIV-1 IN’s relative robustness compared to CA validates
the notion that the extreme fragility of CA is exceptional. Nevertheless, the 35%
of mutations causing lethal defects in HIV-1 IN are tremendously informative, as
mapping to an HIV-1 intasome model indicated their fragility was unevenly
distributed, with nonviable mutants, and particularly those affecting particle
production or integrase incorporation or expression in virions, highly localized to
precise subunit interface regions.
The reasons for the increased robustness of HIV-1 IN, as compared to
HIV-1 CA, are not immediately apparent. Both are relatively conserved proteins
that are absolutely essential to viral replication, lack redundancy, and appear to
have relatively similar rates of variability in vivo (Figure 28A-D), all of which could
be hypothesized to make them equally vulnerable to mutation. However, there
are a number of dissimilarities that could underlie their divergent robustness. As
has been mentioned earlier, capsid must maintain a stable structure than can
adopt a wide range finely tuned and delicately timed CA:CA interactions that
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adjust between immature and mature conformations [110,123,255,256].
Moreover, CA must also form interactions with a wide variety of host proteins,
including nuclear pore complex proteins [131], cyclophilin A [120], and CPSF6
[218]. While IN forms critical interactions with LEDGF [189], as well as
interactions with TRN-SR2(TNPO3) [273] and 1/hSNF5 [274], and also
undergoes multimerization processes [159], there have been no indications that
these interactions or structural requirements are as numerous or as stringent as
those required for CA. Although any one interaction or structural requirement
could theoretically contribute to the observation that significant fitness in CA
occurs only within very limited regions, but occurs more frequently and randomly
within IN, perhaps it is the larger number of specific and constrained CA
interactions (both inter- and intra-protein) and requirements that limits viability to
so few regions (Figure 32A, B). Ultimately, it seems likely that the more
numerous and restrictive requirements necessary for proper and efficient particle
assembly, already established as the basis of HIV-1 CA fragility, result in a
unique fragility for HIV-1 CA, and a relative robustness for IN that is more similar
to other viral proteins. With more studies of robustness in RNA viruses, more
guidelines and critical determinants of robustness will become evident, although
these are likely to vary by protein, as we have seen in this work.
Perhaps the most striking finding of the IN mutagenic analyses is the
localization of many nonviable IN mutants to specific IN subunit interfaces within
the intasome model. Our intention in this work was not to reveal the significance
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of single residues within IN, or to investigate IN catalytic activities, but rather to
use the comprehensive nature of a randomly mutagenized IN library to derive
more extensive understanding of the robustness of IN, and possible regions of
vulnerability in the intasome. For this reason, it was gratifying to observe how
viable and nonviable mutants can be mapped to distinct regions in the intasome
model (Figure 33A-D). It was even more fascinating to observe how precisely
many nonviable mutants affecting specific functional phenotypes, namely
production of particles and IN expression in virions by western blot, can be
mapped to certain subunit interfaces, while nonviable mutants affecting
infectiousness only are scattered in buried positions, without any localized
pattern in the intasome (Figures 35A, B and 36A, B). Such strong and defined
patterns suggest this HIV-1 intasome model is a valid structure for these
analyses. The location of most nonviable mutants impacting particle production
or IN incorporation in virions lies at the interface between the inner (red and blue
regions, Figure 33A) and outer (yellow and green regions, Figure 33A) IN
subunits, approximately mutated IN residues 76-87, 102-113, 132-135, and 178213, and this is largely within the CCD-CCD dimerization interface [159].
Interestingly, the outer subunits of the intasome have previously been reported to
lack any clear role in formation of the tetramer, and their function has not been
clear [159]. This may explain the considerable viability in these regions, although
residues at the edges of the interface with the inner subunit clearly contribute
significant fragility (Figure 33C, D). While previous work has suggested that
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individual residues at the inner-outer subunit, CCD-CCD interface could be
important for multimerization [275,276], none has realized the full extent of the
intolerance to mutation in this region, nor has there been intasome mapping that
so clearly reveals these specific vulnerabilities. However, this interface is
adjacent to, and includes, some critical residues LEDGF uses to bind HIV-1 IN to
affect multimerization [277]. This may explain why therapeutic allosteric
integrase inhibitors (ALLINIs), which engage with IN at the same LEDGF binding
sites (to prevent interaction), are effective at disrupting viral replication [202].
Together, these data suggest that the nonviable IN mutants that affect particle
assembly and IN expression in virions occur at localized regions within the CCDCCD interface on the intasome model, and their fragility may arise because they
disturb critical multimerization or binding steps during the assembly of IN. In
many ways the suggestion that fragile IN residues are largely those affecting
structural dimerization, multimerization, or binding, is analogous to the finding
that fragile CA residues are typically those involved in assembly of particles.
When combined, the data from both IN and CA suggest that specific structural
interactions and requirements during assembly processes are amongst the most
significant determinants of robustness and fragility.
While analysis of the location of the fragile IN mutants is informative, so
too is the analysis of the robust, viable mutants. An interesting commonality
apparent between the IN and CA structural results is the observation that viable
single residue mutants were more likely to occur in surface exposed locations
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with higher solvent accessible surface areas (Figures 15A, C and 33C, E).
Perhaps not intrinsically surprising, as similar data from as far back as the 1960s
suggested haemoglobin residues at the surface were less sensitive to
replacement than more internal residues [278], it is a trend that may be deserving
of more recognition. In the case of HIV-1 IN, these surface residues were also
more variable (Figure 39 A, C), an observation that may also be true for other
proteins under selective pressure, such as HIV-1 envelope [43,279,280], and
which could be used as a predictor of residues more likely to be involved in IN
therapeutic resistance. Given the strong association between solvent accessible
surface area and viability in both HIV-1 IN and CA, it is likely that the same
association exists for other viral proteins, and it is possible that the amount of
surface exposure, which could affect a number of structural interactions, is also a
determinant of robustness.
Investigations of the relationship between the fitness of IN and CA library
mutations and their frequency in naturally occurring HIV-1 subtype B populations
revealed a remarkable shared threshold of 40% of WT replicative fitness, below
which mutants were unlikely to occur frequently (>3%) in vivo (Figure 37A, B).
This suggests such a fitness cut-off may exist for other viral proteins and that
40% of WT may be an accurate estimate of in vivo fitness restrictions. At the
same time, we also noticed that while there were plenty of fit mutants that
occurred frequently in natural populations, a large number of fit IN and CA
mutants occurred either very rarely or never in our cohorts of 1,000 isolate
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sequences (Figure 22C, Table 7). This is intuitively at odds with the expectation
that HIV-1 will take advantage of all available sequence space not severely
impacting fitness. Interestingly, the differential frequency of fit mutants can be
explained for IN, at least in part, by the surface exposure of the fit IN ‘frequent’ or
‘never’ mutants (Figure 38A-C). Once again, those IN residues with greater
surface exposure and higher solvent accessible surface area values were more
likely to occur frequently, whereas more buried residues were more likely to
never occur in isolate sequences (Figure 38A-C). However, such an observation
did not appear to be true for CA (results not shown), in which no significant
differences could be detected between the solvent accessible surface area
values for fit ‘frequent’ and ‘rare’ residues, although in CA’s case, the sample size
for analysis was smaller. As previously discussed, the immune pressure created
by cytotoxic T lymphocytes (CTLs) could potentially suppress the ‘fit but rare’ CA
mutations. While both IN and CA have been documented to be under selective
pressures created by host immune CD8+ CTL responses, there is little to no
evidence of CTL-imposed reductions in replication capacity or viral load
corresponding to Pol/IN, while multiple CTL responses to Gag/CA have been
shown to reduce viral burdens [142,144,148,196,200,264]. The increased
robustness of HIV-1 IN should mean it is less vulnerable to immune pressure, as
it has more successful ‘escape’ options, and this may explain why ‘fit but rare’
mutations in IN are unlikely to be rare because of immune pressure. Ultimately, it
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is conceivable that multiple factors, including divergent ones in IN and CA, may
contribute to the infrequency of some fit mutants in vivo.
The implications of the elevated robustness of HIV-1 IN are not entirely
understood. Less vulnerability to immune pressure is one likely outcome, and
from a clinical standpoint, lower robustness of CA versus IN should help explain
why individuals with immune responses to Gag during HIV-1 infection fare better
than those with immune responses to other viral proteins [148]. Increased
evolvability is also theorized to be positively correlated with higher robustness
[82], as early experiments have already suggested [281].
Summary of HIV-1 IN and CA robustness and associated implications
Through our evaluation of the genetic robustness of two necessary, but
functionally divergent HIV-1 proteins, numerous common attributes were
revealed. Perhaps most interesting is the observation that in both proteins,
fragile residues tended to be those critically involved in the formation of higher
order structures—in CA, fragile residues typically impacted particle assembly in a
manner likely dependent on CA:CA interactions, and in IN, fragile residues were
largely localized to regions associated with multimerization. While perhaps not
inherently surprising, this observation may inform of residues or regions in other
viral proteins that could be similarly vulnerable to mutation. At the same time,
and in accordance with Perutz’s 1968 suggestion [278], we also noted that the
fragile residues in both IN and CA tended to be those in more buried locations,
with lower solvent accessible surface area values. Together, this suggests that,
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generally speaking, residues in more buried positions are likely crucial to the
structural integrity of the protein, such that disruption by substitution can be a
lethal blow to assembling multimers. Finally, we observed a rather surprising
shared cutoff for mutant viability in vivo: in analyses of both IN and CA libraries,
mutants required almost exactly 40% of WT fitness in vitro in order to occur
frequently in natural populations (>3%). This alludes to the presence of a
common threshold at which mutations can confer a selective advantage, and
such a limit may also apply to single amino acid substitutions in other HIV-1 open
reading frames, or even other viruses. Evaluation of these similarities provides
the beginning of a framework in which new structural or functional commonalities
amongst viral proteins might be uncovered.
Nevertheless, our genetic robustness studies often revealed significant
differences between IN and CA. Most obviously, the two differ greatly in their
degree of genetic fragility, with 70% of random single amino acid substitutions in
CA resulting in nonviability, while only 35% of single amino acid substitutions in
IN had the same effect. The comparative robustness of IN was unexpected
given that IN is highly conserved, essential, required to adopt variable
conformations, and shows variability similar to that of CA in vivo. However, as
we have already discussed, the differences in the fragilities of IN and CA likely
reflect each protein’s individual requirements for inter- and intra- protein
interactions. In turn, it seems likely that the disparities between IN and CA’s
fragilities also underlie the differences in each protein’s susceptibility to immune
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pressures, including those imposed by CTLs. Ultimately these differences are
significant, as they indicate that particularly fragile proteins, like HIV-1 capsid,
may be better targets of novel therapies than more robust proteins. Furthermore,
the distinctions between IN and CA highlight how further genetic robustness
studies of additional proteins in HIV-1 might fill in the significant gaps surrounding
our understanding of HIV-1’s evolutionary capacity.
Understanding the genetic robustness and fragility of individual proteins in
HIV-1, like IN and CA, advances our basic understanding of HIV-1 and reveals
how its proteins uniquely cope with pressures induced by high mutation rates and
a hostile host environment. Additionally, evaluation of genetic fragility provides
insight that could help predict: vulnerable regions within protein structures that
could be targeted by novel inhibitors, constraints on sequence space, and
resistance to therapeutic treatments. This may prove vital to better estimating
the evolutionary path of viruses like HIV-1, and may also aid the development of
improved antiviral strategies.
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